PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
22686090-10	2012	CONCLUSIONS: Injecting CCPA into Bahui improved the rats" behavior and histomorphology in the ischemic penumbra, elevated the expressions of Bcl-2 protein, and reduced the neurons apoptosis rate in the ischemic penumbra.	2-chloro-N(6)cyclopentyladenosine	23-27	BCL2, apoptosis regulator	Rattus norvegicus	141-146
22160543-12	2012	CCPA (10(-6) M) increased the protein expression of PKC-alpha and phosphorylated-ERK1/2, while HET0016 significantly reduced the CCPA-induced increase in expression of these proteins.	2-chloro-N(6)cyclopentyladenosine	0-4	protein kinase C, alpha	Mus musculus	52-61
22160543-9	2012	Contraction to CCPA in WT and A(2A)KO aorta was inhibited by PD-98059 (p42/p44 MAPK inhibitor; 10(-6) M), chelerythrine chloride (nonselective PKC blocker; 10(-6) M), Go-6976 (selective PKC-alpha inhibitor; 10(-7) M), and HET0016 (20-HETE inhibitor; 10(-5) M).	2-chloro-N(6)cyclopentyladenosine	15-19	erythrocyte membrane protein band 4.2	Mus musculus	71-74
22160543-12	2012	CCPA (10(-6) M) increased the protein expression of PKC-alpha and phosphorylated-ERK1/2, while HET0016 significantly reduced the CCPA-induced increase in expression of these proteins.	2-chloro-N(6)cyclopentyladenosine	0-4	mitogen-activated protein kinase 3	Mus musculus	81-87
22160543-9	2012	Contraction to CCPA in WT and A(2A)KO aorta was inhibited by PD-98059 (p42/p44 MAPK inhibitor; 10(-6) M), chelerythrine chloride (nonselective PKC blocker; 10(-6) M), Go-6976 (selective PKC-alpha inhibitor; 10(-7) M), and HET0016 (20-HETE inhibitor; 10(-5) M).	2-chloro-N(6)cyclopentyladenosine	15-19	mitogen-activated protein kinase 3	Mus musculus	75-83
20648037-5	2011	This native upregulation is further increased by the selective A1R agonist 2-chloro-N-cyclopentyladenosine (CCPA), whereas the selective antagonist 8-cyclopentyl-1,3-dihydropylxanthine (DPCPX) decreases p-ERK and p-AKT expression.	2-chloro-N(6)cyclopentyladenosine	75-106	mitogen-activated protein kinase 1	Homo sapiens	205-208
22160543-9	2012	Contraction to CCPA in WT and A(2A)KO aorta was inhibited by PD-98059 (p42/p44 MAPK inhibitor; 10(-6) M), chelerythrine chloride (nonselective PKC blocker; 10(-6) M), Go-6976 (selective PKC-alpha inhibitor; 10(-7) M), and HET0016 (20-HETE inhibitor; 10(-5) M).	2-chloro-N(6)cyclopentyladenosine	15-19	protein kinase C, alpha	Mus musculus	143-146
22160543-9	2012	Contraction to CCPA in WT and A(2A)KO aorta was inhibited by PD-98059 (p42/p44 MAPK inhibitor; 10(-6) M), chelerythrine chloride (nonselective PKC blocker; 10(-6) M), Go-6976 (selective PKC-alpha inhibitor; 10(-7) M), and HET0016 (20-HETE inhibitor; 10(-5) M).	2-chloro-N(6)cyclopentyladenosine	15-19	protein kinase C, alpha	Mus musculus	186-195
21460200-5	2011	Benefit with both CCPA and IPC was eliminated by inhibitors of EGFR tyrosine kinase (0.3 muM AG1478), MMP (0.3 muM GM6001), or HB-EGF ligand (0.3 ng/ml CRM197), none of which independently altered postischemic outcome.	2-chloro-N(6)cyclopentyladenosine	18-22	epidermal growth factor receptor	Mus musculus	63-67
21460200-5	2011	Benefit with both CCPA and IPC was eliminated by inhibitors of EGFR tyrosine kinase (0.3 muM AG1478), MMP (0.3 muM GM6001), or HB-EGF ligand (0.3 ng/ml CRM197), none of which independently altered postischemic outcome.	2-chloro-N(6)cyclopentyladenosine	18-22	heparin-binding EGF-like growth factor	Mus musculus	127-133
21946103-7	2011	Finally, adenylyl cyclase inhibition elicited by 2-Chloro-N6-cyclopentyladenosine (CPA), a selective adenosine A1 receptor agonist, was significantly reduced after 12, 24 and 48h of treatment (37, 24 and 23%, respectively) as compared to controls (54%), suggesting the desensitization of adenosine A1 receptor/adenylyl cyclase pathway.	2-chloro-N(6)cyclopentyladenosine	49-81	adenosine A1 receptor	Rattus norvegicus	101-122
21946103-7	2011	Finally, adenylyl cyclase inhibition elicited by 2-Chloro-N6-cyclopentyladenosine (CPA), a selective adenosine A1 receptor agonist, was significantly reduced after 12, 24 and 48h of treatment (37, 24 and 23%, respectively) as compared to controls (54%), suggesting the desensitization of adenosine A1 receptor/adenylyl cyclase pathway.	2-chloro-N(6)cyclopentyladenosine	49-81	adenosine A1 receptor	Rattus norvegicus	288-309
21946103-7	2011	Finally, adenylyl cyclase inhibition elicited by 2-Chloro-N6-cyclopentyladenosine (CPA), a selective adenosine A1 receptor agonist, was significantly reduced after 12, 24 and 48h of treatment (37, 24 and 23%, respectively) as compared to controls (54%), suggesting the desensitization of adenosine A1 receptor/adenylyl cyclase pathway.	2-chloro-N(6)cyclopentyladenosine	83-86	adenosine A1 receptor	Rattus norvegicus	101-122
21946103-7	2011	Finally, adenylyl cyclase inhibition elicited by 2-Chloro-N6-cyclopentyladenosine (CPA), a selective adenosine A1 receptor agonist, was significantly reduced after 12, 24 and 48h of treatment (37, 24 and 23%, respectively) as compared to controls (54%), suggesting the desensitization of adenosine A1 receptor/adenylyl cyclase pathway.	2-chloro-N(6)cyclopentyladenosine	83-86	adenosine A1 receptor	Rattus norvegicus	288-309
22086014-1	2011	OBJECTIVE: To investigate the changes of myocardial protein expression profiles in 2-chloro-N6-cyclopentyladenosine (CCPA), an adenosine A1 receptor agonist-induced delayed myocardial protection in New Zealand rabbits .	2-chloro-N(6)cyclopentyladenosine	83-115	adenosine receptor A1	Oryctolagus cuniculus	127-148
22086014-1	2011	OBJECTIVE: To investigate the changes of myocardial protein expression profiles in 2-chloro-N6-cyclopentyladenosine (CCPA), an adenosine A1 receptor agonist-induced delayed myocardial protection in New Zealand rabbits .	2-chloro-N(6)cyclopentyladenosine	117-121	adenosine receptor A1	Oryctolagus cuniculus	127-148
20648037-5	2011	This native upregulation is further increased by the selective A1R agonist 2-chloro-N-cyclopentyladenosine (CCPA), whereas the selective antagonist 8-cyclopentyl-1,3-dihydropylxanthine (DPCPX) decreases p-ERK and p-AKT expression.	2-chloro-N(6)cyclopentyladenosine	75-106	AKT serine/threonine kinase 1	Homo sapiens	213-218
20648037-5	2011	This native upregulation is further increased by the selective A1R agonist 2-chloro-N-cyclopentyladenosine (CCPA), whereas the selective antagonist 8-cyclopentyl-1,3-dihydropylxanthine (DPCPX) decreases p-ERK and p-AKT expression.	2-chloro-N(6)cyclopentyladenosine	108-112	mitogen-activated protein kinase 1	Homo sapiens	205-208
20648037-5	2011	This native upregulation is further increased by the selective A1R agonist 2-chloro-N-cyclopentyladenosine (CCPA), whereas the selective antagonist 8-cyclopentyl-1,3-dihydropylxanthine (DPCPX) decreases p-ERK and p-AKT expression.	2-chloro-N(6)cyclopentyladenosine	108-112	AKT serine/threonine kinase 1	Homo sapiens	213-218
20363896-8	2010	While CCPA significantly increased the phosphorylation of HSP27, this action was inhibited by isoproterenol.	2-chloro-N(6)cyclopentyladenosine	6-10	heat shock protein family B (small) member 1	Rattus norvegicus	58-63
19861313-10	2010	Cytokine production and leukocyte recruitment were enhanced (2.5-fold) by treatment with an A(1)R agonist (2-chloro-N(6)-cyclopentyladenosine, 0.1 mg/kg) and reduced (2.5-3-fold) by the A(1)R antagonist (8-cyclopentyl-1, 3-dipropylxanthine, 1 mg/kg).	2-chloro-N(6)cyclopentyladenosine	107-141	adenosine A1 receptor	Mus musculus	92-97
20100569-8	2010	2-carbacyclic phosphatidic acid (ccPA 16:1), a small molecule inhibitor of autotaxin, also accelerated apoptosis induced by carboplatin.	2-chloro-N(6)cyclopentyladenosine	33-37	ectonucleotide pyrophosphatase/phosphodiesterase 2	Homo sapiens	75-84
20100569-10	2010	When serum was withdrawn to remove exogenous LPA, ccPA caused a pronounced potentiation of apoptosis induced by carboplatin in cells expressing autotaxin.	2-chloro-N(6)cyclopentyladenosine	50-54	ectonucleotide pyrophosphatase/phosphodiesterase 2	Homo sapiens	144-153
19025536-4	2008	RESULTS: Pre-treatments with adenosine (0.1 and 1 microM) and CCPA (1 microM, adenosine A(1) receptor agonist), but not that with CGS21680 (0.5 microM, A(2) receptor agonist), shifted the rocuronium concentration-twitch tension curves to the left and decreased the rocuronium concentration for 50% twitch depression (IC(50)) compared with the control (P<0.01).	2-chloro-N(6)cyclopentyladenosine	62-66	adenosine A1 receptor	Rattus norvegicus	78-101
19525381-6	2009	Scanning confocal microscopy showed that CCPA caused PKC-epsilon to reversibly colocalize with RACK2 within 3 min.	2-chloro-N(6)cyclopentyladenosine	41-45	protein kinase C, epsilon	Mus musculus	53-64
19525381-9	2009	Western blotting showed that CCPA, phenylisopropyladenosine, and phorbol 12-myristate 13-acetate in the rat heart increased the PKC-epsilon co-IP with RACK2 by 186, 49, and >1,000%, respectively.	2-chloro-N(6)cyclopentyladenosine	29-33	protein kinase C, epsilon	Mus musculus	128-139
19208896-5	2009	Conversely, SLI release was inhibited by the A(1) receptor agonists N(6)-cyclopentyladenosine and 2-chloro-N(6)-cyclopentyladenosine and lower concentration of adenosine (0.01 microM).	2-chloro-N(6)cyclopentyladenosine	98-132	SHC (Src homology 2 domain containing) transforming protein 2	Mus musculus	12-15
19242639-11	2009	Fluorescence microscopy of cryosections taken from the left ventricle 30 min after CCPA injection revealed a large increase in the number of mCherry-LC3-labeled structures, indicating the induction of autophagy by CCPA in vivo.	2-chloro-N(6)cyclopentyladenosine	83-87	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	149-152
19242639-11	2009	Fluorescence microscopy of cryosections taken from the left ventricle 30 min after CCPA injection revealed a large increase in the number of mCherry-LC3-labeled structures, indicating the induction of autophagy by CCPA in vivo.	2-chloro-N(6)cyclopentyladenosine	214-218	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	149-152
17965278-7	2008	The greatest difference between H(2)O(2) and CCPA was in the Triton-insoluble membrane fraction, where H(2)O(2) increased p38 and p42 activation and CCPA reduced MAPK activation.	2-chloro-N(6)cyclopentyladenosine	45-49	mitogen activated protein kinase 14	Rattus norvegicus	122-125
18181173-7	2008	Treatment of wild-type hearts with the A(1)R agonist CCPA increased the total PP2A activity and increased the particulate:cytoplasmic PP2A activity ratio.	2-chloro-N(6)cyclopentyladenosine	53-57	protein phosphatase 2, regulatory subunit A, alpha	Mus musculus	78-82
18181173-7	2008	Treatment of wild-type hearts with the A(1)R agonist CCPA increased the total PP2A activity and increased the particulate:cytoplasmic PP2A activity ratio.	2-chloro-N(6)cyclopentyladenosine	53-57	protein phosphatase 2, regulatory subunit A, alpha	Mus musculus	134-138
18416820-8	2008	Notably, expression of the operons encoding non-hemolytic enterotoxin (Nhe) and hemolytic enterotoxin (Hbl) was affected by ccpA deletion, and putative CRE-sites were identified, which suggests catabolite repression of the enterotoxin operons to be CcpA-dependent.	2-chloro-N(6)cyclopentyladenosine	124-128	C40 family peptidase	Bacillus cereus ATCC 14579	58-69
18416820-8	2008	Notably, expression of the operons encoding non-hemolytic enterotoxin (Nhe) and hemolytic enterotoxin (Hbl) was affected by ccpA deletion, and putative CRE-sites were identified, which suggests catabolite repression of the enterotoxin operons to be CcpA-dependent.	2-chloro-N(6)cyclopentyladenosine	124-128	C40 family peptidase	Bacillus cereus ATCC 14579	90-101
18416820-8	2008	Notably, expression of the operons encoding non-hemolytic enterotoxin (Nhe) and hemolytic enterotoxin (Hbl) was affected by ccpA deletion, and putative CRE-sites were identified, which suggests catabolite repression of the enterotoxin operons to be CcpA-dependent.	2-chloro-N(6)cyclopentyladenosine	124-128	C40 family peptidase	Bacillus cereus ATCC 14579	90-101
18416820-8	2008	Notably, expression of the operons encoding non-hemolytic enterotoxin (Nhe) and hemolytic enterotoxin (Hbl) was affected by ccpA deletion, and putative CRE-sites were identified, which suggests catabolite repression of the enterotoxin operons to be CcpA-dependent.	2-chloro-N(6)cyclopentyladenosine	249-253	C40 family peptidase	Bacillus cereus ATCC 14579	58-69
18416820-8	2008	Notably, expression of the operons encoding non-hemolytic enterotoxin (Nhe) and hemolytic enterotoxin (Hbl) was affected by ccpA deletion, and putative CRE-sites were identified, which suggests catabolite repression of the enterotoxin operons to be CcpA-dependent.	2-chloro-N(6)cyclopentyladenosine	249-253	C40 family peptidase	Bacillus cereus ATCC 14579	90-101
18416820-8	2008	Notably, expression of the operons encoding non-hemolytic enterotoxin (Nhe) and hemolytic enterotoxin (Hbl) was affected by ccpA deletion, and putative CRE-sites were identified, which suggests catabolite repression of the enterotoxin operons to be CcpA-dependent.	2-chloro-N(6)cyclopentyladenosine	249-253	C40 family peptidase	Bacillus cereus ATCC 14579	90-101
17965278-3	2008	Adult rat cardiomyocytes were exposed to the adenosine A(1) receptor agonist 2-chloro-N(6)-cyclopentyladenosine (CCPA; 500 nM) or H(2)O(2) (100 microM) for 15 min.	2-chloro-N(6)cyclopentyladenosine	77-111	adenosine A1 receptor	Rattus norvegicus	45-68
17965278-5	2008	CCPA and H(2)O(2) activated p38 MAPK and p44/p42 ERKs in cytosolic fractions.	2-chloro-N(6)cyclopentyladenosine	0-4	mitogen activated protein kinase 14	Rattus norvegicus	28-31
18490761-4	2008	Furthermore, CX(3)CL1-induced neuroprotection from Glu toxicity is mediated through the adenosine receptor 1 (AR(1)), being blocked by neuronal cell preparations treatment with 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), a specific inhibitor of AR(1), and mimicked by both adenosine and the specific AR(1) agonist 2-chloro-N(6)-cyclopentyladenosine.	2-chloro-N(6)cyclopentyladenosine	314-348	chemokine (C-X3-C motif) ligand 1	Mus musculus	13-21
18054348-8	2008	Our results, besides showing that adenosine A1 receptor prompts mammalian spermatozoa to undergo the acrosome reaction hence supporting a role for adenosine as agent for fertilisation, show that 2-chloro-N6-cyclopentyladenosine triggers signalling mechanisms that involve both Galpha(i2) and G(q/11), extracellular calcium influx, modulation of classical Ca2+-dependent PCK isoforms and up-regulation of the ERK1/2 phosphorylation.	2-chloro-N(6)cyclopentyladenosine	195-227	succinate-CoA ligase GDP/ADP-forming subunit alpha	Homo sapiens	277-286
18054348-8	2008	Our results, besides showing that adenosine A1 receptor prompts mammalian spermatozoa to undergo the acrosome reaction hence supporting a role for adenosine as agent for fertilisation, show that 2-chloro-N6-cyclopentyladenosine triggers signalling mechanisms that involve both Galpha(i2) and G(q/11), extracellular calcium influx, modulation of classical Ca2+-dependent PCK isoforms and up-regulation of the ERK1/2 phosphorylation.	2-chloro-N(6)cyclopentyladenosine	195-227	mitogen-activated protein kinase 3	Homo sapiens	408-414
17965278-7	2008	The greatest difference between H(2)O(2) and CCPA was in the Triton-insoluble membrane fraction, where H(2)O(2) increased p38 and p42 activation and CCPA reduced MAPK activation.	2-chloro-N(6)cyclopentyladenosine	149-153	mitogen activated protein kinase 3	Rattus norvegicus	162-166
17965278-5	2008	CCPA and H(2)O(2) activated p38 MAPK and p44/p42 ERKs in cytosolic fractions.	2-chloro-N(6)cyclopentyladenosine	0-4	mitogen activated protein kinase 3	Rattus norvegicus	32-36
17293559-4	2007	Both in control astrocytes and in astrocytes exposed to OGD, CCPA and LY379268 induced a rapid activation of the phosphatidylinositol-3-kinase (PI3K) and extracellular signal-regulated kinases 1 and 2 (ERK1/2)/mitogen-activated protein kinase (MAPK) pathways, which are known to support cell survival.	2-chloro-N(6)cyclopentyladenosine	61-65	mitogen-activated protein kinase 1	Homo sapiens	154-200
17965278-5	2008	CCPA and H(2)O(2) activated p38 MAPK and p44/p42 ERKs in cytosolic fractions.	2-chloro-N(6)cyclopentyladenosine	0-4	mitogen activated protein kinase 3	Rattus norvegicus	41-44
17965278-5	2008	CCPA and H(2)O(2) activated p38 MAPK and p44/p42 ERKs in cytosolic fractions.	2-chloro-N(6)cyclopentyladenosine	0-4	mitogen activated protein kinase 3	Rattus norvegicus	49-53
17921328-4	2007	The adenosine A(1) receptor agonist 2-chloro-N(6)-cyclopentyladenosine (CCPA; 0.05 mg/kg) also exerted a cytoprotective effect, which was selectively blocked by the A(1) antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX; 0.2 mg/kg).	2-chloro-N(6)cyclopentyladenosine	36-70	adenosine A1 receptor	Mus musculus	4-27
17921328-4	2007	The adenosine A(1) receptor agonist 2-chloro-N(6)-cyclopentyladenosine (CCPA; 0.05 mg/kg) also exerted a cytoprotective effect, which was selectively blocked by the A(1) antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX; 0.2 mg/kg).	2-chloro-N(6)cyclopentyladenosine	72-76	adenosine A1 receptor	Mus musculus	4-27
17376479-2	2007	Unlike other LacI-GalR proteins, CcpA is activated to bind DNA by binding the phosphoproteins HPr-Ser46-P or Crh-Ser46-P.	2-chloro-N(6)cyclopentyladenosine	33-37	haptoglobin-related protein	Homo sapiens	94-97
17376479-2	2007	Unlike other LacI-GalR proteins, CcpA is activated to bind DNA by binding the phosphoproteins HPr-Ser46-P or Crh-Ser46-P.	2-chloro-N(6)cyclopentyladenosine	33-37	corticotropin releasing hormone	Homo sapiens	109-112
17376479-3	2007	However, fine regulation of CCR is accomplished by the small molecule effectors, glucose 6-phosphate (G6P) and fructose 1,6-bisphosphate (FBP), which somehow enhance CcpA-(HPr-Ser46-P) binding to DNA.	2-chloro-N(6)cyclopentyladenosine	166-170	fructose-bisphosphatase 1	Homo sapiens	138-141
17376479-3	2007	However, fine regulation of CCR is accomplished by the small molecule effectors, glucose 6-phosphate (G6P) and fructose 1,6-bisphosphate (FBP), which somehow enhance CcpA-(HPr-Ser46-P) binding to DNA.	2-chloro-N(6)cyclopentyladenosine	166-170	haptoglobin-related protein	Homo sapiens	172-175
17376479-4	2007	Unlike the CcpA-(HPr-Ser46-P) complex, DNA binding by CcpA-(Crh-Ser46-P) is not stimulated by G6P or FBP.	2-chloro-N(6)cyclopentyladenosine	54-58	corticotropin releasing hormone	Homo sapiens	60-63
17376479-5	2007	To understand the fine-tuning mechanism of these effectors, we solved the structures of the CcpA core, DeltaCcpA, which lacks the N-terminal DNA-binding domain, in complex with HPr-Ser46-P and G6P or FBP.	2-chloro-N(6)cyclopentyladenosine	92-96	haptoglobin-related protein	Homo sapiens	177-180
17376479-5	2007	To understand the fine-tuning mechanism of these effectors, we solved the structures of the CcpA core, DeltaCcpA, which lacks the N-terminal DNA-binding domain, in complex with HPr-Ser46-P and G6P or FBP.	2-chloro-N(6)cyclopentyladenosine	92-96	fructose-bisphosphatase 1	Homo sapiens	200-203
17376479-6	2007	G6P and FBP bind in a deep cleft, between the N and C subdomains of CcpA.	2-chloro-N(6)cyclopentyladenosine	68-72	fructose-bisphosphatase 1	Homo sapiens	8-11
17376479-8	2007	This suggests that one role of the adjunct corepressors is to buttress the DNA-binding conformation effected by the binding of HPr-Ser46-P to the CcpA dimer N subdomains.	2-chloro-N(6)cyclopentyladenosine	146-150	haptoglobin-related protein	Homo sapiens	127-130
17376479-9	2007	However, the structures reveal that an unexpected function of adjunct corepressor binding is to bolster cross interactions between HPr-Ser46-P residue Arg17 and residues Asp69 and Asp99 of the other CcpA subunit.	2-chloro-N(6)cyclopentyladenosine	199-203	haptoglobin-related protein	Homo sapiens	131-134
17376479-10	2007	These cross contacts, which are weak or not present in the CcpA-(Crh-Ser46-P) complex, stimulate the CcpA-(HPr-Ser46-P)-DNA interaction specifically.	2-chloro-N(6)cyclopentyladenosine	59-63	corticotropin releasing hormone	Homo sapiens	65-68
17376479-10	2007	These cross contacts, which are weak or not present in the CcpA-(Crh-Ser46-P) complex, stimulate the CcpA-(HPr-Ser46-P)-DNA interaction specifically.	2-chloro-N(6)cyclopentyladenosine	59-63	haptoglobin-related protein	Homo sapiens	107-110
17376479-10	2007	These cross contacts, which are weak or not present in the CcpA-(Crh-Ser46-P) complex, stimulate the CcpA-(HPr-Ser46-P)-DNA interaction specifically.	2-chloro-N(6)cyclopentyladenosine	101-105	corticotropin releasing hormone	Homo sapiens	65-68
17376479-10	2007	These cross contacts, which are weak or not present in the CcpA-(Crh-Ser46-P) complex, stimulate the CcpA-(HPr-Ser46-P)-DNA interaction specifically.	2-chloro-N(6)cyclopentyladenosine	101-105	haptoglobin-related protein	Homo sapiens	107-110
17376479-11	2007	Thus, stabilization of the closed conformation and bolstering of cross contacts between CcpA and its other corepressor, HPr-Ser46-P, provide a molecular explanation for how adjunct corepressors G6P and FBP enhance the interaction between CcpA-(HPr-Ser46-P) and cognate DNA.	2-chloro-N(6)cyclopentyladenosine	88-92	haptoglobin-related protein	Homo sapiens	120-123
17376479-11	2007	Thus, stabilization of the closed conformation and bolstering of cross contacts between CcpA and its other corepressor, HPr-Ser46-P, provide a molecular explanation for how adjunct corepressors G6P and FBP enhance the interaction between CcpA-(HPr-Ser46-P) and cognate DNA.	2-chloro-N(6)cyclopentyladenosine	88-92	fructose-bisphosphatase 1	Homo sapiens	202-205
17376479-11	2007	Thus, stabilization of the closed conformation and bolstering of cross contacts between CcpA and its other corepressor, HPr-Ser46-P, provide a molecular explanation for how adjunct corepressors G6P and FBP enhance the interaction between CcpA-(HPr-Ser46-P) and cognate DNA.	2-chloro-N(6)cyclopentyladenosine	88-92	haptoglobin-related protein	Homo sapiens	244-247
17376479-11	2007	Thus, stabilization of the closed conformation and bolstering of cross contacts between CcpA and its other corepressor, HPr-Ser46-P, provide a molecular explanation for how adjunct corepressors G6P and FBP enhance the interaction between CcpA-(HPr-Ser46-P) and cognate DNA.	2-chloro-N(6)cyclopentyladenosine	238-242	haptoglobin-related protein	Homo sapiens	120-123
17376479-11	2007	Thus, stabilization of the closed conformation and bolstering of cross contacts between CcpA and its other corepressor, HPr-Ser46-P, provide a molecular explanation for how adjunct corepressors G6P and FBP enhance the interaction between CcpA-(HPr-Ser46-P) and cognate DNA.	2-chloro-N(6)cyclopentyladenosine	238-242	fructose-bisphosphatase 1	Homo sapiens	202-205
17376479-11	2007	Thus, stabilization of the closed conformation and bolstering of cross contacts between CcpA and its other corepressor, HPr-Ser46-P, provide a molecular explanation for how adjunct corepressors G6P and FBP enhance the interaction between CcpA-(HPr-Ser46-P) and cognate DNA.	2-chloro-N(6)cyclopentyladenosine	238-242	haptoglobin-related protein	Homo sapiens	244-247
17928414-5	2007	Pretreatment with a selective A(1)AR agonist 2-chloro-N(6)-cyclopentyladenosine (CCPA; 0.1 mg/kg bolus ip) either 15 min or 24 h before renal ischemia protected against renal IR injury and reduced renal corticomedullary necrosis, apoptosis, and inflammation.	2-chloro-N(6)cyclopentyladenosine	45-79	adenosine A1 receptor	Mus musculus	30-36
17928414-7	2007	Moreover, induction of HSP27 and Akt occurred with CCPA treatment.	2-chloro-N(6)cyclopentyladenosine	51-55	heat shock protein 1	Mus musculus	23-28
17928414-7	2007	Moreover, induction of HSP27 and Akt occurred with CCPA treatment.	2-chloro-N(6)cyclopentyladenosine	51-55	thymoma viral proto-oncogene 1	Mus musculus	33-36
17317007-1	2007	This study was undertaken in order to investigate the effect of 2-chloro-2"-C-methyl-N(6)-cyclopentyladenosine (2"-Me-CCPA), a potent and highly selective adenosine A(1) receptor agonist, on nociceptive responses and on the ongoing or tail flick-related changes of rostral ventromedial medulla (RVM) ON- and OFF-cell activities.	2-chloro-N(6)cyclopentyladenosine	118-122	adenosine A1 receptor	Rattus norvegicus	155-178
17400382-4	2007	CCPA also caused a dose- and time-dependent phosphorylation/activation of Akt, a downstream effector of cell survival promoting phosphatidylinositol 3-kinase (PI3K) pathway, which in turn led to inhibition of staurosporine-induced GSK3beta and p38 MAPK activity.	2-chloro-N(6)cyclopentyladenosine	0-4	AKT serine/threonine kinase 1	Rattus norvegicus	74-77
17400382-4	2007	CCPA also caused a dose- and time-dependent phosphorylation/activation of Akt, a downstream effector of cell survival promoting phosphatidylinositol 3-kinase (PI3K) pathway, which in turn led to inhibition of staurosporine-induced GSK3beta and p38 MAPK activity.	2-chloro-N(6)cyclopentyladenosine	0-4	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta	Rattus norvegicus	128-157
17400382-4	2007	CCPA also caused a dose- and time-dependent phosphorylation/activation of Akt, a downstream effector of cell survival promoting phosphatidylinositol 3-kinase (PI3K) pathway, which in turn led to inhibition of staurosporine-induced GSK3beta and p38 MAPK activity.	2-chloro-N(6)cyclopentyladenosine	0-4	glycogen synthase kinase 3 beta	Rattus norvegicus	231-239
17400382-4	2007	CCPA also caused a dose- and time-dependent phosphorylation/activation of Akt, a downstream effector of cell survival promoting phosphatidylinositol 3-kinase (PI3K) pathway, which in turn led to inhibition of staurosporine-induced GSK3beta and p38 MAPK activity.	2-chloro-N(6)cyclopentyladenosine	0-4	mitogen activated protein kinase 14	Rattus norvegicus	244-247
17293559-2	2007	We show that pharmacological activation of A(1) adenosine and mGlu3 metabotropic glutamate receptors with N(6)-chlorocyclopentyladenosine (CCPA) and (-)2-oxa-4-aminocyclo-[3.1.0]hexane-4,6-dicarboxylic acid (LY379268), respectively, protects cultured astrocytes against apoptosis induced by a 3-h exposure to oxygen/glucose deprivation (OGD).	2-chloro-N(6)cyclopentyladenosine	139-143	glutamate receptor, metabotropic 3	Mus musculus	62-67
17293559-4	2007	Both in control astrocytes and in astrocytes exposed to OGD, CCPA and LY379268 induced a rapid activation of the phosphatidylinositol-3-kinase (PI3K) and extracellular signal-regulated kinases 1 and 2 (ERK1/2)/mitogen-activated protein kinase (MAPK) pathways, which are known to support cell survival.	2-chloro-N(6)cyclopentyladenosine	61-65	mitogen-activated protein kinase 3	Homo sapiens	202-208
17293559-5	2007	In cultures exposed to OGD, CCPA and LY379268 reduced the activation of c-Jun N-terminal kinase and p38/MAPK, reduced the levels of the proapoptotic protein Bad, increased the levels of the antiapoptotic protein Bcl-X(L), and were highly protective against apoptotic death, as shown by nuclear 4"-6-diamidino-2-phenylindole staining and measurements of caspase-3 activity.	2-chloro-N(6)cyclopentyladenosine	28-32	mitogen-activated protein kinase 1	Homo sapiens	100-103
17293559-5	2007	In cultures exposed to OGD, CCPA and LY379268 reduced the activation of c-Jun N-terminal kinase and p38/MAPK, reduced the levels of the proapoptotic protein Bad, increased the levels of the antiapoptotic protein Bcl-X(L), and were highly protective against apoptotic death, as shown by nuclear 4"-6-diamidino-2-phenylindole staining and measurements of caspase-3 activity.	2-chloro-N(6)cyclopentyladenosine	28-32	BCL2 like 1	Homo sapiens	212-220
17293559-5	2007	In cultures exposed to OGD, CCPA and LY379268 reduced the activation of c-Jun N-terminal kinase and p38/MAPK, reduced the levels of the proapoptotic protein Bad, increased the levels of the antiapoptotic protein Bcl-X(L), and were highly protective against apoptotic death, as shown by nuclear 4"-6-diamidino-2-phenylindole staining and measurements of caspase-3 activity.	2-chloro-N(6)cyclopentyladenosine	28-32	caspase 3	Homo sapiens	353-362
17085448-10	2007	Mutations of the residues of CcpA, which contact Arg-17 of HPr, exhibit differential effects on regulation of catabolic genes.	2-chloro-N(6)cyclopentyladenosine	29-33	haptoglobin-related protein	Homo sapiens	59-62
16913720-5	2006	In particular, the phosphonothioate ccPA analogue inhibited Ca2+ release through LPA1/LPA3 activation and was an LPA1/LPA3 antagonist.	2-chloro-N(6)cyclopentyladenosine	36-40	lysophosphatidic acid receptor 1	Rattus norvegicus	81-85
17085448-2	2007	HPr-Ser46-P or Crh-Ser46-P interact with CcpA and stimulate binding to catabolite responsive elements.	2-chloro-N(6)cyclopentyladenosine	41-45	haptoglobin-related protein	Homo sapiens	0-3
17085448-2	2007	HPr-Ser46-P or Crh-Ser46-P interact with CcpA and stimulate binding to catabolite responsive elements.	2-chloro-N(6)cyclopentyladenosine	41-45	corticotropin releasing hormone	Homo sapiens	15-18
17085448-3	2007	In addition, the glycolytic intermediates fructose 1,6-bisphosphate (FBP) and glucose 6-phosphate (Glc-6-P) stimulate HPr-Ser46-P but not Crh-Ser46-P binding to CcpA.	2-chloro-N(6)cyclopentyladenosine	161-165	fructose-bisphosphatase 1	Homo sapiens	69-72
17085448-5	2007	To address this question we mutated residues participating in the interaction between HPr-Ser46-P or Crh-Ser46-P and CcpA and analyzed their effects on CcpA binding and stimulation of cre binding by surface plasmon resonance.	2-chloro-N(6)cyclopentyladenosine	117-121	corticotropin releasing hormone	Homo sapiens	101-104
17311505-3	2007	RESULTS: The T allele at T1492C and G allele at G1649C of SP-A2 were observed at slightly higher frequencies in ABPA patients (86% and 93%) than in controls (63% and 83%), and the C alleles at position 1492 and 1649 were found in higher frequencies in CCPA patients (33% and 25%) than in ABPA patients (14% and 7%) (all p>0.05).	2-chloro-N(6)cyclopentyladenosine	252-256	surfactant protein A2	Homo sapiens	58-63
17311505-6	2007	In the case of MBL, the T allele (OR=3.1, range 1.2-8.9; p< or =0.02) and CT genotype (chi(2)=6.54; p(corr)< or =0.05) at position 868 (codon 52) were significantly associated with CCPA, but not with ABPA.	2-chloro-N(6)cyclopentyladenosine	187-191	mannose binding lectin 2	Homo sapiens	15-18
17311505-9	2007	CONCLUSIONS: Distinct alleles, genotypes and genotype combinations of SP-A2 and MBL may contribute to differential susceptibility of the host to CCPA or ABPA.	2-chloro-N(6)cyclopentyladenosine	145-149	surfactant protein A2	Homo sapiens	70-75
17311505-9	2007	CONCLUSIONS: Distinct alleles, genotypes and genotype combinations of SP-A2 and MBL may contribute to differential susceptibility of the host to CCPA or ABPA.	2-chloro-N(6)cyclopentyladenosine	145-149	mannose binding lectin 2	Homo sapiens	80-83
16913720-5	2006	In particular, the phosphonothioate ccPA analogue inhibited Ca2+ release through LPA1/LPA3 activation and was an LPA1/LPA3 antagonist.	2-chloro-N(6)cyclopentyladenosine	36-40	lysophosphatidic acid receptor 3	Rattus norvegicus	86-90
16913720-5	2006	In particular, the phosphonothioate ccPA analogue inhibited Ca2+ release through LPA1/LPA3 activation and was an LPA1/LPA3 antagonist.	2-chloro-N(6)cyclopentyladenosine	36-40	lysophosphatidic acid receptor 1	Rattus norvegicus	113-117
16913720-5	2006	In particular, the phosphonothioate ccPA analogue inhibited Ca2+ release through LPA1/LPA3 activation and was an LPA1/LPA3 antagonist.	2-chloro-N(6)cyclopentyladenosine	36-40	lysophosphatidic acid receptor 3	Rattus norvegicus	118-122
16913720-6	2006	The monofluoromethylene phosphonate ccPA analogue was also a potent LPA1/LPA3 antagonist.	2-chloro-N(6)cyclopentyladenosine	36-40	lysophosphatidic acid receptor 1	Rattus norvegicus	68-72
16913720-6	2006	The monofluoromethylene phosphonate ccPA analogue was also a potent LPA1/LPA3 antagonist.	2-chloro-N(6)cyclopentyladenosine	36-40	lysophosphatidic acid receptor 3	Rattus norvegicus	73-77
16750892-5	2006	An A(1) receptor agonist, 2-chloro-N(6)-cyclopentyladenosine (100 nM), caused a transient increase, followed by a transient decrease, in DARPP-32 Thr34 phosphorylation.	2-chloro-N(6)cyclopentyladenosine	26-60	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	137-145
16316990-0	2006	Phosphoprotein Crh-Ser46-P displays altered binding to CcpA to effect carbon catabolite regulation.	2-chloro-N(6)cyclopentyladenosine	55-59	corticotropin releasing hormone	Homo sapiens	15-18
16893395-4	2006	We have profiled functional cytokine gene polymorphisms for interleukin (IL)-10, IL-15, transforming growth factors (TGF)-beta1, tumour necrosis factor (TNF)-alpha and interferon (IFN)-gamma in patients with CCPA (n = 24) who were compared with other forms of aspergillosis (mostly ABPA) (n = 15) and with ethnically matched controls (n = 65-330).	2-chloro-N(6)cyclopentyladenosine	208-212	interferon gamma	Homo sapiens	168-190
16893395-9	2006	CCPA occurs in patients who are genetically lower producers of both IL-10 and TGF-beta1.	2-chloro-N(6)cyclopentyladenosine	0-4	interleukin 10	Homo sapiens	68-73
16893395-9	2006	CCPA occurs in patients who are genetically lower producers of both IL-10 and TGF-beta1.	2-chloro-N(6)cyclopentyladenosine	0-4	transforming growth factor beta 1	Homo sapiens	78-87
16517942-4	2006	In addition, selective activation of A1AR with 2-chloro-N6-cyclopentyladenosine (CCPA) at nanomolar concentrations (1-100 nM) did not significantly change coronary flow; at higher concentrations, CCPA increased coronary flow in A1AR(-/-) and A1AR(+/+) hearts.	2-chloro-N(6)cyclopentyladenosine	47-79	adenosine A1 receptor	Mus musculus	37-41
16517942-4	2006	In addition, selective activation of A1AR with 2-chloro-N6-cyclopentyladenosine (CCPA) at nanomolar concentrations (1-100 nM) did not significantly change coronary flow; at higher concentrations, CCPA increased coronary flow in A1AR(-/-) and A1AR(+/+) hearts.	2-chloro-N(6)cyclopentyladenosine	81-85	adenosine A1 receptor	Mus musculus	37-41
16517942-4	2006	In addition, selective activation of A1AR with 2-chloro-N6-cyclopentyladenosine (CCPA) at nanomolar concentrations (1-100 nM) did not significantly change coronary flow; at higher concentrations, CCPA increased coronary flow in A1AR(-/-) and A1AR(+/+) hearts.	2-chloro-N(6)cyclopentyladenosine	196-200	adenosine A1 receptor	Mus musculus	37-41
16316990-5	2006	To understand the molecular mechanism of Crh-Ser46-P regulation of CCR, we determined the structure of a CcpA-(Crh-Ser46-P)-DNA complex.	2-chloro-N(6)cyclopentyladenosine	105-109	corticotropin releasing hormone	Homo sapiens	41-44
16316990-5	2006	To understand the molecular mechanism of Crh-Ser46-P regulation of CCR, we determined the structure of a CcpA-(Crh-Ser46-P)-DNA complex.	2-chloro-N(6)cyclopentyladenosine	105-109	corticotropin releasing hormone	Homo sapiens	111-114
16100051-6	2005	This interpretation is supported by the finding that adenosine- and CCPA-induced phosphorylation of ERK, JNK, and AKT are inhibited by pertussis toxin (inactivator of Gi proteins) and by DPCPX (A1-selective antagonist), but not by SCH58261, MRS1706, and VUF5574 (A2A-, A2B-, and A3-selective antagonists, respectively).	2-chloro-N(6)cyclopentyladenosine	68-72	mitogen-activated protein kinase 1	Homo sapiens	100-103
16006548-6	2005	In iNOS-/- mice, however, the late PC effect elicited by DETA/NO, NTG, SNAP, TAN-670, and CCPA was completely abrogated.	2-chloro-N(6)cyclopentyladenosine	90-94	nitric oxide synthase 2, inducible	Mus musculus	3-7
16006548-7	2005	Furthermore, in WT mice pretreated with TAN-670 or CCPA, the selective iNOS inhibitor 1400W also abolished the delayed PC properties of these drugs; 1400W had no effect in WT mice.	2-chloro-N(6)cyclopentyladenosine	51-55	nitric oxide synthase 2, inducible	Mus musculus	71-75
16143649-4	2006	A1R activation with 2-chloro-N6-cyclopentyladenosine (CCPA) resulted in a 27% reduction in contractile response to the beta-adrenergic agonist isoproterenol (ISO).	2-chloro-N(6)cyclopentyladenosine	20-52	adenosine A1 receptor	Mus musculus	0-3
16143649-4	2006	A1R activation with 2-chloro-N6-cyclopentyladenosine (CCPA) resulted in a 27% reduction in contractile response to the beta-adrenergic agonist isoproterenol (ISO).	2-chloro-N(6)cyclopentyladenosine	54-58	adenosine A1 receptor	Mus musculus	0-3
16100051-6	2005	This interpretation is supported by the finding that adenosine- and CCPA-induced phosphorylation of ERK, JNK, and AKT are inhibited by pertussis toxin (inactivator of Gi proteins) and by DPCPX (A1-selective antagonist), but not by SCH58261, MRS1706, and VUF5574 (A2A-, A2B-, and A3-selective antagonists, respectively).	2-chloro-N(6)cyclopentyladenosine	68-72	mitogen-activated protein kinase 8	Homo sapiens	105-108
16100051-6	2005	This interpretation is supported by the finding that adenosine- and CCPA-induced phosphorylation of ERK, JNK, and AKT are inhibited by pertussis toxin (inactivator of Gi proteins) and by DPCPX (A1-selective antagonist), but not by SCH58261, MRS1706, and VUF5574 (A2A-, A2B-, and A3-selective antagonists, respectively).	2-chloro-N(6)cyclopentyladenosine	68-72	AKT serine/threonine kinase 1	Homo sapiens	114-117
16100051-7	2005	In addition, adenosine- and CCPA-induced phosphorylation of ERK, JNK, and AKT is inhibited, respectively, by U0126, PD98059 (mitogen-activated protein kinase kinase inhibitors), SP600125 (JNK kinase inhibitor), and wortmannin (phosphatidylinositol 3-kinase inhibitor).	2-chloro-N(6)cyclopentyladenosine	28-32	mitogen-activated protein kinase 1	Homo sapiens	60-63
16100051-7	2005	In addition, adenosine- and CCPA-induced phosphorylation of ERK, JNK, and AKT is inhibited, respectively, by U0126, PD98059 (mitogen-activated protein kinase kinase inhibitors), SP600125 (JNK kinase inhibitor), and wortmannin (phosphatidylinositol 3-kinase inhibitor).	2-chloro-N(6)cyclopentyladenosine	28-32	mitogen-activated protein kinase 8	Homo sapiens	65-68
16100051-7	2005	In addition, adenosine- and CCPA-induced phosphorylation of ERK, JNK, and AKT is inhibited, respectively, by U0126, PD98059 (mitogen-activated protein kinase kinase inhibitors), SP600125 (JNK kinase inhibitor), and wortmannin (phosphatidylinositol 3-kinase inhibitor).	2-chloro-N(6)cyclopentyladenosine	28-32	AKT serine/threonine kinase 1	Homo sapiens	74-77
16100051-7	2005	In addition, adenosine- and CCPA-induced phosphorylation of ERK, JNK, and AKT is inhibited, respectively, by U0126, PD98059 (mitogen-activated protein kinase kinase inhibitors), SP600125 (JNK kinase inhibitor), and wortmannin (phosphatidylinositol 3-kinase inhibitor).	2-chloro-N(6)cyclopentyladenosine	28-32	mitogen-activated protein kinase 8	Homo sapiens	188-191
14665673-5	2003	Homologues of HPr kinase are commonly observed in the phylum Firmicutes but are also found in the phyla Proteobacteria, Fusobacteria, Spirochaetes, and Chlorobi, suggesting that CcpA-dependent CCR is not restricted to gram-positive bacteria.	2-chloro-N(6)cyclopentyladenosine	178-182	haptoglobin-related protein	Homo sapiens	14-17
15833799-7	2005	Treatment with CCPA reduced infarct size from 48 +/- 2 to 28 +/- 2% of the area at risk, an effect that was blocked by both SB-203580 and PD-098059 but not 1400 W. Ventricular myocytes isolated 24 h after CCPA injection exhibited significantly reduced oxidative stress during H2O2 exposure compared with myocytes from vehicle-injected animals, and this effect was not blocked by the iNOS inhibitor 1400 W. Western blot analysis of whole heart and cardiac myocyte protein samples revealed no expression of iNOS 6 or 24 h after CCPA treatment.	2-chloro-N(6)cyclopentyladenosine	15-19	nitric oxide synthase 2	Rattus norvegicus	383-387
15833799-7	2005	Treatment with CCPA reduced infarct size from 48 +/- 2 to 28 +/- 2% of the area at risk, an effect that was blocked by both SB-203580 and PD-098059 but not 1400 W. Ventricular myocytes isolated 24 h after CCPA injection exhibited significantly reduced oxidative stress during H2O2 exposure compared with myocytes from vehicle-injected animals, and this effect was not blocked by the iNOS inhibitor 1400 W. Western blot analysis of whole heart and cardiac myocyte protein samples revealed no expression of iNOS 6 or 24 h after CCPA treatment.	2-chloro-N(6)cyclopentyladenosine	15-19	nitric oxide synthase 2	Rattus norvegicus	505-509
15025935-3	2004	Hearts treated with CCPA improved in terms of mechanical function, infarct size, ATP levels, superoxide dismutase, and catalase (p < 0.005) in both modes of administration.	2-chloro-N(6)cyclopentyladenosine	20-24	catalase	Rattus norvegicus	119-127
14603270-8	2004	Furthermore, pretreatment with CCPA (3 mg/kg) attenuated significantly the dizocilpine-induced expression of HSP-70 protein, which is known as a sensitive marker of reversible neuronal damage, and coadministration with DPCPX (3 mg/kg) blocked the inhibitory effects of CCPA for marked expression of HSP-70 protein by administration of dizocilpine.	2-chloro-N(6)cyclopentyladenosine	31-35	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	109-115
14603270-8	2004	Furthermore, pretreatment with CCPA (3 mg/kg) attenuated significantly the dizocilpine-induced expression of HSP-70 protein, which is known as a sensitive marker of reversible neuronal damage, and coadministration with DPCPX (3 mg/kg) blocked the inhibitory effects of CCPA for marked expression of HSP-70 protein by administration of dizocilpine.	2-chloro-N(6)cyclopentyladenosine	31-35	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	299-305
14603270-8	2004	Furthermore, pretreatment with CCPA (3 mg/kg) attenuated significantly the dizocilpine-induced expression of HSP-70 protein, which is known as a sensitive marker of reversible neuronal damage, and coadministration with DPCPX (3 mg/kg) blocked the inhibitory effects of CCPA for marked expression of HSP-70 protein by administration of dizocilpine.	2-chloro-N(6)cyclopentyladenosine	269-273	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	109-115
14600029-8	2004	In addition, A1WT mice pretreated with DPCPX or CCPA showed significantly increased or reduced markers of renal inflammation, respectively (renal myeloperoxidase activity, renal tubular neutrophil infiltration, ICAM-1, TNF-alpha, and IL-1beta mRNA expression), while demonstrating no differences in indicators of apoptosis.	2-chloro-N(6)cyclopentyladenosine	48-52	myeloperoxidase	Mus musculus	146-161
14600029-8	2004	In addition, A1WT mice pretreated with DPCPX or CCPA showed significantly increased or reduced markers of renal inflammation, respectively (renal myeloperoxidase activity, renal tubular neutrophil infiltration, ICAM-1, TNF-alpha, and IL-1beta mRNA expression), while demonstrating no differences in indicators of apoptosis.	2-chloro-N(6)cyclopentyladenosine	48-52	intercellular adhesion molecule 1	Mus musculus	211-217
14600029-8	2004	In addition, A1WT mice pretreated with DPCPX or CCPA showed significantly increased or reduced markers of renal inflammation, respectively (renal myeloperoxidase activity, renal tubular neutrophil infiltration, ICAM-1, TNF-alpha, and IL-1beta mRNA expression), while demonstrating no differences in indicators of apoptosis.	2-chloro-N(6)cyclopentyladenosine	48-52	tumor necrosis factor	Mus musculus	219-228
14600029-8	2004	In addition, A1WT mice pretreated with DPCPX or CCPA showed significantly increased or reduced markers of renal inflammation, respectively (renal myeloperoxidase activity, renal tubular neutrophil infiltration, ICAM-1, TNF-alpha, and IL-1beta mRNA expression), while demonstrating no differences in indicators of apoptosis.	2-chloro-N(6)cyclopentyladenosine	48-52	interleukin 1 beta	Mus musculus	234-242
15539423-7	2005	Adenosine and NECA (0.1 microM) caused small contractions of 13.9 +/- 3.0 and 16.4 +/- 6.4%, respectively, and CCPA at 0.1 and 1.0 microM caused contractions of 30.8 +/- 4.3 and 28.1 +/- 3.9%, respectively, in A(1)AR((+/+)) rings.	2-chloro-N(6)cyclopentyladenosine	111-115	adenosine A1 receptor	Mus musculus	210-216
15539423-8	2005	NECA- and CCPA-induced contractions were eliminated by 100 nM of 1,3-dipropyl-8-cyclopentylxanthine (DPCPX, selective A(1)AR antagonist).	2-chloro-N(6)cyclopentyladenosine	10-14	adenosine A1 receptor	Mus musculus	118-124
15539423-10	2005	CCPA-induced contraction at 1.0 microM was eliminated by the PLC inhibitor U-73122.	2-chloro-N(6)cyclopentyladenosine	0-4	perlecan (heparan sulfate proteoglycan 2)	Mus musculus	61-64
15066904-17	2004	We demonstrated that, at high K(+) concentrations, endogenous AD occupies A1 receptors, impairing the action of CCPA, since incubation with 8-cyclopentyl-1,3-dipropylxanthine (DPCPX, an A(1) receptor antagonist) and adenosine deaminase (ADA), which degrades AD into the inactive metabolite inosine, increased mepp frequency compared with that obtained in 15 and 20 mm K(+) in the absence of the drugs.	2-chloro-N(6)cyclopentyladenosine	112-116	adenosine deaminase	Mus musculus	186-235
15066904-17	2004	We demonstrated that, at high K(+) concentrations, endogenous AD occupies A1 receptors, impairing the action of CCPA, since incubation with 8-cyclopentyl-1,3-dipropylxanthine (DPCPX, an A(1) receptor antagonist) and adenosine deaminase (ADA), which degrades AD into the inactive metabolite inosine, increased mepp frequency compared with that obtained in 15 and 20 mm K(+) in the absence of the drugs.	2-chloro-N(6)cyclopentyladenosine	112-116	adenosine deaminase	Mus musculus	237-240
15066904-18	2004	Moreover, CCPA was able to induce presynaptic inhibition in the presence of ADA.	2-chloro-N(6)cyclopentyladenosine	10-14	adenosine deaminase	Mus musculus	76-79
14577586-4	2003	Pretreatment with the A1 adenosine receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA, 1 microM), abolished the effects of Ang II on programmed cardiomyocyte death.	2-chloro-N(6)cyclopentyladenosine	52-84	angiotensinogen	Rattus norvegicus	128-134
14577586-4	2003	Pretreatment with the A1 adenosine receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA, 1 microM), abolished the effects of Ang II on programmed cardiomyocyte death.	2-chloro-N(6)cyclopentyladenosine	86-90	angiotensinogen	Rattus norvegicus	128-134
12856829-5	2003	The cellular resistance was acquired by iNOS-/- mice myocytes due to HS, SSI, CCPA, S-ENBA, pinacidil and diazoxide treatment, which was evidenced by reduction of LDH (U/L) release from 51.14 +/- 1.35 (iNOS-/-) to 42.20 +/- 1.01 (iNOS-/- + HS); 45.57 +/- 0.75 (iNOS-/- + SSI); 42.87 +/- 0.87 (iNOS-/- + CCPA); 43.21 +/- 0.70 (iNOS-/- + S-ENBA); 37.81 +/- 0.99 (iNOS-/- + Pin) and 36.79 +/- 0.68 (iNOS-/- + Diazo), p < 0.01.	2-chloro-N(6)cyclopentyladenosine	78-82	nitric oxide synthase 2, inducible	Mus musculus	40-44
12644893-8	2003	Further, SSI and the A(1)AR agonists CCPA or S-ENBA induce further, delayed cytoprotection in A(1)AR-tgm.	2-chloro-N(6)cyclopentyladenosine	37-41	adenosine A1 receptor	Mus musculus	21-27
12644893-8	2003	Further, SSI and the A(1)AR agonists CCPA or S-ENBA induce further, delayed cytoprotection in A(1)AR-tgm.	2-chloro-N(6)cyclopentyladenosine	37-41	adenosine A1 receptor	Mus musculus	94-100
12856829-5	2003	The cellular resistance was acquired by iNOS-/- mice myocytes due to HS, SSI, CCPA, S-ENBA, pinacidil and diazoxide treatment, which was evidenced by reduction of LDH (U/L) release from 51.14 +/- 1.35 (iNOS-/-) to 42.20 +/- 1.01 (iNOS-/- + HS); 45.57 +/- 0.75 (iNOS-/- + SSI); 42.87 +/- 0.87 (iNOS-/- + CCPA); 43.21 +/- 0.70 (iNOS-/- + S-ENBA); 37.81 +/- 0.99 (iNOS-/- + Pin) and 36.79 +/- 0.68 (iNOS-/- + Diazo), p < 0.01.	2-chloro-N(6)cyclopentyladenosine	303-307	nitric oxide synthase 2, inducible	Mus musculus	40-44
12021208-4	2002	This stimulation, however, was not observed in either GH(3) or AtT20 cells, where adenosine and the A(1) receptor agonist 2-chloro-N(6)-cyclopentyladenosine inhibited VIP/forskolin-stimulated cAMP production.	2-chloro-N(6)cyclopentyladenosine	122-156	vasoactive intestinal polypeptide	Mus musculus	167-170
12593531-6	2002	CCPA increased the expression of A1AR (1.30 fold), epsilon-PKC (1.20 fold), iNOS (1.50 fold), and HSP 72i (1.70 fold) compared to the controls.	2-chloro-N(6)cyclopentyladenosine	0-4	inositol-3-phosphate synthase 1	Homo sapiens	76-80
12593531-7	2002	CCPA-induced up-regulation of A1AR, epsilon-PKC, iNOS, HSP 72i, and the opening of both mitochondrial and sarcolemmal KATP channels may possibly participate in signaling cascade.	2-chloro-N(6)cyclopentyladenosine	0-4	inositol-3-phosphate synthase 1	Homo sapiens	49-53
12063302-2	2002	This study investigates the PKC signaling pathway in the late PC induced by activation of adenosine A(1) receptor (A(1)R) with adenosine agonist 2-chloro-N(6)-cyclopentyladenosine (CCPA) and the effect on iNOS upregulation.	2-chloro-N(6)cyclopentyladenosine	145-179	protein kinase C, delta	Mus musculus	28-31
12063302-2	2002	This study investigates the PKC signaling pathway in the late PC induced by activation of adenosine A(1) receptor (A(1)R) with adenosine agonist 2-chloro-N(6)-cyclopentyladenosine (CCPA) and the effect on iNOS upregulation.	2-chloro-N(6)cyclopentyladenosine	145-179	adenosine A1 receptor	Mus musculus	90-113
12063302-2	2002	This study investigates the PKC signaling pathway in the late PC induced by activation of adenosine A(1) receptor (A(1)R) with adenosine agonist 2-chloro-N(6)-cyclopentyladenosine (CCPA) and the effect on iNOS upregulation.	2-chloro-N(6)cyclopentyladenosine	181-185	protein kinase C, delta	Mus musculus	28-31
12063302-2	2002	This study investigates the PKC signaling pathway in the late PC induced by activation of adenosine A(1) receptor (A(1)R) with adenosine agonist 2-chloro-N(6)-cyclopentyladenosine (CCPA) and the effect on iNOS upregulation.	2-chloro-N(6)cyclopentyladenosine	181-185	adenosine A1 receptor	Mus musculus	90-113
12063302-9	2002	Immunoblotting of PKC showed that PKC-delta was upregulated (150.0 +/- 11.4% of control group) whereas other PKC isoforms remained unchanged, and iNOS was also significantly increased (146.2 +/- 9.0%, P < 0.05 vs. control group) after 24 h of treatment with CCPA.	2-chloro-N(6)cyclopentyladenosine	261-265	protein kinase C, delta	Mus musculus	34-43
12063302-9	2002	Immunoblotting of PKC showed that PKC-delta was upregulated (150.0 +/- 11.4% of control group) whereas other PKC isoforms remained unchanged, and iNOS was also significantly increased (146.2 +/- 9.0%, P < 0.05 vs. control group) after 24 h of treatment with CCPA.	2-chloro-N(6)cyclopentyladenosine	261-265	protein kinase C, delta	Mus musculus	34-37
12063302-9	2002	Immunoblotting of PKC showed that PKC-delta was upregulated (150.0 +/- 11.4% of control group) whereas other PKC isoforms remained unchanged, and iNOS was also significantly increased (146.2 +/- 9.0%, P < 0.05 vs. control group) after 24 h of treatment with CCPA.	2-chloro-N(6)cyclopentyladenosine	261-265	nitric oxide synthase 2, inducible	Mus musculus	146-150
12270497-10	2002	However, treatment with the selective A(1) agonist CCPA attenuated the CA3 cell loss (P<0.05 versus other treatment).	2-chloro-N(6)cyclopentyladenosine	51-55	carbonic anhydrase 3	Mus musculus	71-74
12044789-0	2002	2-Chloro-N(6)-cyclopentyladenosine, adenosine A(1) receptor agonist, antagonizes the adenosine A(3) receptor.	2-chloro-N(6)cyclopentyladenosine	0-34	adenosine receptor A1	Cricetulus griseus	36-59
12044789-0	2002	2-Chloro-N(6)-cyclopentyladenosine, adenosine A(1) receptor agonist, antagonizes the adenosine A(3) receptor.	2-chloro-N(6)cyclopentyladenosine	0-34	adenosine A3 receptor	Homo sapiens	85-108
12044789-1	2002	The potent adenosine A(1) receptor agonists, N(6)-cyclopentyladenosine (CPA) and 2-chloro-N(6)-cyclopentyladenosine (CCPA), were studied in Chinese hamster ovary (CHO) cells expressing the human adenosine A(3) receptor.	2-chloro-N(6)cyclopentyladenosine	117-121	adenosine receptor A1	Cricetulus griseus	11-34
11454603-8	2001	The selective COX-2 inhibitor N-(2-[cyclohexyloxy]4-nitrophenyl)methanesulfonamide (NS-398, 5 mg/kg), which abolished the protective effect of ischemic late PC, failed to block the protection of either CCPA or IB-MECA, indicating that COX-2 does not mediate the delayed protection of either CCPA or IB-MECA [CCPA + NS-398, 29.1 +/- 3.4% (n = 7); IB-MECA + NS-398, 34.9 +/- 2.9% (n = 8)].	2-chloro-N(6)cyclopentyladenosine	202-206	prostaglandin G/H synthase 2	Oryctolagus cuniculus	14-19
11454603-1	2001	Recent studies have demonstrated that the adenosine A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA) and the adenosine A3 receptor agonist N6-(3-iodobenzyl)adenosine-5"-N-methyluronamide (IB-MECA) produce a delayed phase of protection against infarction similar to the late phase of ischemic preconditioning (PC).	2-chloro-N(6)cyclopentyladenosine	72-104	adenosine receptor A1	Oryctolagus cuniculus	42-63
11454603-8	2001	The selective COX-2 inhibitor N-(2-[cyclohexyloxy]4-nitrophenyl)methanesulfonamide (NS-398, 5 mg/kg), which abolished the protective effect of ischemic late PC, failed to block the protection of either CCPA or IB-MECA, indicating that COX-2 does not mediate the delayed protection of either CCPA or IB-MECA [CCPA + NS-398, 29.1 +/- 3.4% (n = 7); IB-MECA + NS-398, 34.9 +/- 2.9% (n = 8)].	2-chloro-N(6)cyclopentyladenosine	291-295	prostaglandin G/H synthase 2	Oryctolagus cuniculus	14-19
11454603-1	2001	Recent studies have demonstrated that the adenosine A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA) and the adenosine A3 receptor agonist N6-(3-iodobenzyl)adenosine-5"-N-methyluronamide (IB-MECA) produce a delayed phase of protection against infarction similar to the late phase of ischemic preconditioning (PC).	2-chloro-N(6)cyclopentyladenosine	106-110	adenosine receptor A1	Oryctolagus cuniculus	42-63
11454603-8	2001	The selective COX-2 inhibitor N-(2-[cyclohexyloxy]4-nitrophenyl)methanesulfonamide (NS-398, 5 mg/kg), which abolished the protective effect of ischemic late PC, failed to block the protection of either CCPA or IB-MECA, indicating that COX-2 does not mediate the delayed protection of either CCPA or IB-MECA [CCPA + NS-398, 29.1 +/- 3.4% (n = 7); IB-MECA + NS-398, 34.9 +/- 2.9% (n = 8)].	2-chloro-N(6)cyclopentyladenosine	291-295	prostaglandin G/H synthase 2	Oryctolagus cuniculus	14-19
11179074-2	2001	Adult male mice were treated with vehicle (5% DMSO) or the A(1)AR agonist 2-chloro-N(6)-cyclopentyladenosine (CCPA; 0.1 mg/kg ip).	2-chloro-N(6)cyclopentyladenosine	74-108	adenosine A1 receptor	Mus musculus	59-65
11179074-5	2001	given 30 min before CCPA treatment was used to block receptor tyrosine kinase or p38 MAPK phosphorylation, respectively.	2-chloro-N(6)cyclopentyladenosine	20-24	mitogen-activated protein kinase 14	Mus musculus	81-84
11179074-9	2001	CCPA treatment also caused increased phosphorylation of p38 MAPK during ischemia, which was blocked by genistein, SB-203580, and 5-HD.	2-chloro-N(6)cyclopentyladenosine	0-4	mitogen-activated protein kinase 14	Mus musculus	56-64
10859291-11	2000	CCPA treatment induced a significant increase in myocardial Mn-SOD content and activity compared with the control condition; this increase was abolished by pretreatment with antisense ODN.	2-chloro-N(6)cyclopentyladenosine	0-4	superoxide dismutase 2	Rattus norvegicus	60-66
10952960-3	2000	METHODS AND RESULTS: Adult male mice were treated with saline or an A(1)AR agonist, 2-chloro-N(6)-cyclopentyladenosine (CCPA).	2-chloro-N(6)cyclopentyladenosine	84-118	adenosine A1 receptor	Mus musculus	68-74
10952960-12	2000	Increased iNOS protein expression observed in CCPA-treated hearts was diminished by DPCPX.	2-chloro-N(6)cyclopentyladenosine	46-50	nitric oxide synthase 2, inducible	Mus musculus	10-14
11238974-9	2001	Mutations in EII(Man) or CcpA resulted in a relief of catabolite repression exerted by EII(Man) substrates on the activity of beta-galactosidase and beta-glucosidase, indicating that EII(Man) and CcpA are important components in catabolite repression in L. pentosus.	2-chloro-N(6)cyclopentyladenosine	25-29	galactosidase beta 1	Homo sapiens	126-144
10644577-3	2000	The adenosine A(1) receptor agonist 2-chloro-N(6)-cyclopentlyadenosine (CCPA) reduced isoproterenol-stimulated [Ca(2+)](i) and contractility by 87 and 80%, respectively, but reduced cAMP content by only 18%.	2-chloro-N(6)cyclopentyladenosine	72-76	adenosine A1 receptor	Rattus norvegicus	4-27
10758093-10	2000	A selective adenosine A(1) receptor agonist (CCPA) reduced the histamine-activated current and a selective adenosine A(1) receptor antagonist (CPT) reversed the inhibitory action.	2-chloro-N(6)cyclopentyladenosine	45-49	adenosine receptor A1	Cavia porcellus	12-35
8906843-5	1996	2-Chloro-N6-cyclopentyladenosine (CCPA), an agonist of A1 adenosine receptors, at 0.5 mg/kg diminished LPS-induced plasma TNF-alpha concentrations, but enhanced LPS-induced IL-10 levels only at the highest dose used (2 mg/kg).	2-chloro-N(6)cyclopentyladenosine	0-32	tumor necrosis factor	Mus musculus	122-131
10511627-1	1999	The present study was undertaken to determine whether 2-chloro-N6-cyclopentyladenosine (CCPA), a highly selective A1 adenosine receptor agonist, attenuated cochlear dysfunction induced by transient ischemia or not.	2-chloro-N(6)cyclopentyladenosine	54-86	adenosine receptor A1	Cavia porcellus	114-135
10511627-1	1999	The present study was undertaken to determine whether 2-chloro-N6-cyclopentyladenosine (CCPA), a highly selective A1 adenosine receptor agonist, attenuated cochlear dysfunction induced by transient ischemia or not.	2-chloro-N(6)cyclopentyladenosine	88-92	adenosine receptor A1	Cavia porcellus	114-135
10413299-8	1999	Cd2+ pretreatment reduced the [3H]CCPA affinity, but did not modify the affinity of the antagonist [3H]DPCPX, the Bmax remaining unaffected.	2-chloro-N(6)cyclopentyladenosine	34-38	Cd2 molecule	Rattus norvegicus	0-3
9797030-2	1998	To examine the role of adenosine on the ischemia-evoked release of neurotransmitters, we applied a highly selective agonist for adenosine A1 receptor, 2-chloro-N6-cyclopentyladenosine (CCPA), into the ischemic brain using in vivo brain dialysis, which directly delivered the agonist to the local brain area.	2-chloro-N(6)cyclopentyladenosine	151-183	adenosine A1 receptor	Rattus norvegicus	128-149
9600575-1	1998	The effect of the selective adenosine A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA) was investigated in CD1 mice by the elevated plus-maze and the light/dark test, two models for measuring anxiety in rodents.	2-chloro-N(6)cyclopentyladenosine	58-90	CD1 antigen complex	Mus musculus	118-121
9600575-1	1998	The effect of the selective adenosine A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA) was investigated in CD1 mice by the elevated plus-maze and the light/dark test, two models for measuring anxiety in rodents.	2-chloro-N(6)cyclopentyladenosine	92-96	CD1 antigen complex	Mus musculus	118-121
9543251-8	1998	A partial pharmacological characterization of the binding of the adenosine A1 receptor agonist [3H]CCPA (2-chloro-N6-cyclopentyl[2,3,4,5-(3)H]adenosine), and the adenosine A1 receptor antagonist [3H]DPCPX (cyclopentyl-1,3-dipropyl[2,3-(3)H]xanthine), to HT29 cells is also provided.	2-chloro-N(6)cyclopentyladenosine	95-103	adenosine A1 receptor	Homo sapiens	65-86
9543251-8	1998	A partial pharmacological characterization of the binding of the adenosine A1 receptor agonist [3H]CCPA (2-chloro-N6-cyclopentyl[2,3,4,5-(3)H]adenosine), and the adenosine A1 receptor antagonist [3H]DPCPX (cyclopentyl-1,3-dipropyl[2,3-(3)H]xanthine), to HT29 cells is also provided.	2-chloro-N(6)cyclopentyladenosine	95-103	adenosine A1 receptor	Homo sapiens	162-183
9334231-2	1997	We present evidence that CcpA interacts with HPr that is phosphorylated at Ser46 (Ser(P) HPr) and that these proteins form a specific ternary complex with cre DNA.	2-chloro-N(6)cyclopentyladenosine	25-29	haptoglobin-related protein	Homo sapiens	45-48
9334231-2	1997	We present evidence that CcpA interacts with HPr that is phosphorylated at Ser46 (Ser(P) HPr) and that these proteins form a specific ternary complex with cre DNA.	2-chloro-N(6)cyclopentyladenosine	25-29	haptoglobin-related protein	Homo sapiens	89-92
9334231-7	1997	This allows CcpA to recognize the phosphorylation state of HPr, effectively linking the process of sugar import via the PTS to catabolite repression in bacilli.	2-chloro-N(6)cyclopentyladenosine	12-16	haptoglobin-related protein	Homo sapiens	59-62
8906843-8	1996	In the RAW 264.7 macrophage cell line, pretreatment of the cells with both CGS and CCPA inhibited LPS-induced IL-10, TNF-alpha, and NO production, each in a concentration-dependent manner.	2-chloro-N(6)cyclopentyladenosine	83-87	interleukin 10	Mus musculus	110-115
8906843-8	1996	In the RAW 264.7 macrophage cell line, pretreatment of the cells with both CGS and CCPA inhibited LPS-induced IL-10, TNF-alpha, and NO production, each in a concentration-dependent manner.	2-chloro-N(6)cyclopentyladenosine	83-87	tumor necrosis factor	Mus musculus	117-126
10617136-2	2000	In the present study the effects that acetate has on cerebral intermediary metabolism, compared with those of glucose, were studied using the adenosine A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA) and antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX).	2-chloro-N(6)cyclopentyladenosine	206-210	adenosine A1 receptor	Rattus norvegicus	142-163
9573174-14	1998	Despite this loss of transcriptional regulation in the ccpA mutant strain, beta-galactosidase activity is still reduced by glucose, suggesting another level of control.	2-chloro-N(6)cyclopentyladenosine	55-59	beta-galactosidase	Staphylococcus xylosus	75-93
9475512-4	1998	produced significant increases in [3H]CCPA binding in CA1 subarea at seizure (15%) and postseizure (21%) and in CA2 at seizure (15%) but a tendency to decrease in dentate gyrus.	2-chloro-N(6)cyclopentyladenosine	38-42	carbonic anhydrase 1	Rattus norvegicus	54-57
9475512-7	1998	enhanced [3H]CCPA binding in CA1 and CA2 areas (17-18%) but not in CA3 area of the hippocampus.	2-chloro-N(6)cyclopentyladenosine	13-17	carbonic anhydrase 1	Rattus norvegicus	29-32
9475512-7	1998	enhanced [3H]CCPA binding in CA1 and CA2 areas (17-18%) but not in CA3 area of the hippocampus.	2-chloro-N(6)cyclopentyladenosine	13-17	carbonic anhydrase 2	Rattus norvegicus	37-40
9475512-8	1998	When CPA was administered before MP, which delayed seizure onset, an increase in [3H]CCPA binding in CA1 hippocampus subarea (19%) and cerebellum (28%) was also observed.	2-chloro-N(6)cyclopentyladenosine	85-89	carbonic anhydrase 1	Rattus norvegicus	101-104
9375692-2	1997	Both adenosine and an adenosine A1 receptor agonist, 2-chloro-N6-cyclopentyladenosine, decreased extracellular 5-HT levels, whereas an adenosine A1 receptor antagonist, 8-cyclopentyl-1,3-dimethylxanthine (CPT), and caffeine increased these levels.	2-chloro-N(6)cyclopentyladenosine	53-85	adenosine A1 receptor	Rattus norvegicus	22-43
8906843-5	1996	2-Chloro-N6-cyclopentyladenosine (CCPA), an agonist of A1 adenosine receptors, at 0.5 mg/kg diminished LPS-induced plasma TNF-alpha concentrations, but enhanced LPS-induced IL-10 levels only at the highest dose used (2 mg/kg).	2-chloro-N(6)cyclopentyladenosine	0-32	interleukin 10	Mus musculus	173-178
8906843-5	1996	2-Chloro-N6-cyclopentyladenosine (CCPA), an agonist of A1 adenosine receptors, at 0.5 mg/kg diminished LPS-induced plasma TNF-alpha concentrations, but enhanced LPS-induced IL-10 levels only at the highest dose used (2 mg/kg).	2-chloro-N(6)cyclopentyladenosine	34-38	tumor necrosis factor	Mus musculus	122-131
8906843-5	1996	2-Chloro-N6-cyclopentyladenosine (CCPA), an agonist of A1 adenosine receptors, at 0.5 mg/kg diminished LPS-induced plasma TNF-alpha concentrations, but enhanced LPS-induced IL-10 levels only at the highest dose used (2 mg/kg).	2-chloro-N(6)cyclopentyladenosine	34-38	interleukin 10	Mus musculus	173-178
8075885-11	1994	8FB-PTP and CGS 15943 also antagonized competitively the negative chronotropic response induced by CCPA.	2-chloro-N(6)cyclopentyladenosine	99-103	solute carrier family 25 member 3	Bos taurus	4-7
8782077-12	1996	Adenosine, CCPA, APNEA, BNECA and DPCPX each appear to be selective for the A1 adenosine receptor subtype in isolated rabbit cardiomyocytes.	2-chloro-N(6)cyclopentyladenosine	11-15	adenosine receptor A1	Oryctolagus cuniculus	76-97
8640599-6	1996	Protection from CCPA was completely blocked by 200 nM DPCPX (8-cyclopentyl-1,3-dipropylxanthine) with 34 +/- 7% infarction (P < 0.05 versus CCPA) confirming that protection was via the A1 adenosine receptor.	2-chloro-N(6)cyclopentyladenosine	16-20	adenosine receptor A1	Oryctolagus cuniculus	188-209
12013498-7	1996	Plasma renin activity also changed in opposite directions, being decreased by CCPA but increased dose-dependently by 2HE-NECA and CGS 21680 and only moderately by NECA.	2-chloro-N(6)cyclopentyladenosine	78-82	renin	Rattus norvegicus	7-12
7843263-3	1994	The adenosine A1 receptor antagonist PACPX (1,3-dipropyl-8-(2-amino-4-chloro)phenylxanthine, 1 microM) antagonized the effects of CCPA on heart rate and left ventricular actively developed pressure and increased the EC50 values 11-fold and 8-fold, respectively.	2-chloro-N(6)cyclopentyladenosine	130-134	adenosine receptor A1	Cavia porcellus	4-25
2163017-7	1990	The A1-adenosine receptor-selective antagonist 8-cyclopentyl-1,3-dipropylxanthine antagonized the effect of 2-chloro-N6-cyclopentyladenosine concentration-dependently, with a KB value of 9.6 nM.	2-chloro-N(6)cyclopentyladenosine	108-140	adenosine receptor A1	Cavia porcellus	4-25
1409251-1	1992	The effect of the adenosine receptor agonists, 2-chloro-N6-cyclopentyladenosine (CCPA) and 2-hexynyl-adenosine-5"-N-ethylcarboxamide (HENECA) on atrial natriuretic factor (ANF) release was investigated.	2-chloro-N(6)cyclopentyladenosine	47-79	natriuretic peptide A	Rattus norvegicus	145-170
1409251-2	1992	The A1 adenosine receptor agonist CCPA markedly increased plasma ANF levels, following subcutaneous (s.c.), but not intracerebroventricular injection.	2-chloro-N(6)cyclopentyladenosine	34-38	natriuretic peptide A	Rattus norvegicus	65-68
1409251-3	1992	ANF release evoked by the s.c. injection of CCPA was completely abolished by s.c. pretreatment with the selective A1 adenosine receptor antagonist, 1,3-dipropyl-8-cyclopentylxanthine.	2-chloro-N(6)cyclopentyladenosine	44-48	natriuretic peptide A	Rattus norvegicus	0-3
1409251-6	1992	Preliminary results show that CCPA produces ANF release also from isolated atria, thus suggesting that its action on ANF release is, at least in part, direct, and not only a consequence of cardiovascular modifications.	2-chloro-N(6)cyclopentyladenosine	30-34	natriuretic peptide A	Rattus norvegicus	44-47
1409251-6	1992	Preliminary results show that CCPA produces ANF release also from isolated atria, thus suggesting that its action on ANF release is, at least in part, direct, and not only a consequence of cardiovascular modifications.	2-chloro-N(6)cyclopentyladenosine	30-34	natriuretic peptide A	Rattus norvegicus	117-120
2151470-0	1990	The A1 adenosine receptor agonist 2-chloro-N6-cyclopentyl adenosine (CCPA) potently stimulates the release of atrial natriuretic factor in the rat.	2-chloro-N(6)cyclopentyladenosine	34-67	natriuretic peptide A	Rattus norvegicus	110-135
2151470-0	1990	The A1 adenosine receptor agonist 2-chloro-N6-cyclopentyl adenosine (CCPA) potently stimulates the release of atrial natriuretic factor in the rat.	2-chloro-N(6)cyclopentyladenosine	69-73	natriuretic peptide A	Rattus norvegicus	110-135
33511551-4	2021	NECA (adenosine-analog) and CCPA (adenosine A1 receptor-agonist)-induced dose-dependent vascular response was tested with t-AUCB (sEH-inhibitor) and angiotensin-II (Ang-II) in A2AAR-/- vs. C57Bl/6 mice.	2-chloro-N(6)cyclopentyladenosine	28-32	adenosine A1 receptor	Mus musculus	34-55
34831394-6	2021	By contrast, the A1R agonist CCPA enhanced IR damage, intracellular steatosis and oxidative species (OS) production, thereby further increasing the lipid/OS-dependent ASK1-JNK stimulation.	2-chloro-N(6)cyclopentyladenosine	29-33	adenosine A1 receptor	Mus musculus	17-20
34831394-6	2021	By contrast, the A1R agonist CCPA enhanced IR damage, intracellular steatosis and oxidative species (OS) production, thereby further increasing the lipid/OS-dependent ASK1-JNK stimulation.	2-chloro-N(6)cyclopentyladenosine	29-33	mitogen-activated protein kinase kinase kinase 5	Mus musculus	167-171
34831394-6	2021	By contrast, the A1R agonist CCPA enhanced IR damage, intracellular steatosis and oxidative species (OS) production, thereby further increasing the lipid/OS-dependent ASK1-JNK stimulation.	2-chloro-N(6)cyclopentyladenosine	29-33	mitogen-activated protein kinase 8	Mus musculus	172-175
34831394-7	2021	The CGS2680 and CCPA effects were nullified by a genetic ASK1 downregulation in steatotic hepatoma C1C7 cells.	2-chloro-N(6)cyclopentyladenosine	16-20	mitogen-activated protein kinase kinase kinase 5	Mus musculus	57-61
34831394-8	2021	In steatotic mice livers, CGS21680 protected against hepatic IRI and ASK1/JNK activation whereas CCPA aggravated hepatic steatosis and IRI, and enhanced ASK1 and JNK stimulation.	2-chloro-N(6)cyclopentyladenosine	97-101	mitogen-activated protein kinase kinase kinase 5	Mus musculus	153-157
34831394-8	2021	In steatotic mice livers, CGS21680 protected against hepatic IRI and ASK1/JNK activation whereas CCPA aggravated hepatic steatosis and IRI, and enhanced ASK1 and JNK stimulation.	2-chloro-N(6)cyclopentyladenosine	97-101	mitogen-activated protein kinase 8	Mus musculus	162-165
34831394-9	2021	These results evidence a novel mechanism of CGS21680-mediated hepatoprotection, i.e., the PI3K/AKT-dependent inhibition of ASK1, and they show that CGS21680 and CCPA reduces and enhances the IRI of fatty liver, respectively, by preventing or increasing the activation of the cytotoxic ASK1/JNK axis.	2-chloro-N(6)cyclopentyladenosine	161-165	mitogen-activated protein kinase kinase kinase 5	Mus musculus	285-289
34831394-9	2021	These results evidence a novel mechanism of CGS21680-mediated hepatoprotection, i.e., the PI3K/AKT-dependent inhibition of ASK1, and they show that CGS21680 and CCPA reduces and enhances the IRI of fatty liver, respectively, by preventing or increasing the activation of the cytotoxic ASK1/JNK axis.	2-chloro-N(6)cyclopentyladenosine	161-165	mitogen-activated protein kinase 8	Mus musculus	290-293
34554273-6	2021	The levels of CodY and CcpA, important regulators involved in the stationary phase adaptation and catabolite repression, respectively, also increased in the presence of the bacteriocin.	2-chloro-N(6)cyclopentyladenosine	23-27	bacteriocin	Staphylococcus aureus	173-184
33592249-4	2021	In this study, using metabolically stabilized cPA carba-derivative (2ccPA)-immobilized magnetic beads, we identified adenine nucleotide translocase 2 (ANT2) as a 2ccPA-interacting protein in microglial cells.	2-chloro-N(6)cyclopentyladenosine	68-73	solute carrier family 25 member 6	Homo sapiens	117-149
33592249-4	2021	In this study, using metabolically stabilized cPA carba-derivative (2ccPA)-immobilized magnetic beads, we identified adenine nucleotide translocase 2 (ANT2) as a 2ccPA-interacting protein in microglial cells.	2-chloro-N(6)cyclopentyladenosine	68-73	solute carrier family 25 member 6	Homo sapiens	151-155
33592249-4	2021	In this study, using metabolically stabilized cPA carba-derivative (2ccPA)-immobilized magnetic beads, we identified adenine nucleotide translocase 2 (ANT2) as a 2ccPA-interacting protein in microglial cells.	2-chloro-N(6)cyclopentyladenosine	162-167	solute carrier family 25 member 6	Homo sapiens	117-149
33592249-4	2021	In this study, using metabolically stabilized cPA carba-derivative (2ccPA)-immobilized magnetic beads, we identified adenine nucleotide translocase 2 (ANT2) as a 2ccPA-interacting protein in microglial cells.	2-chloro-N(6)cyclopentyladenosine	162-167	solute carrier family 25 member 6	Homo sapiens	151-155
33592249-7	2021	This is the first report to suggest the direct binding of 2ccPA to ANT2 in microglial cells and provides evidence for a new benefit of 2ccPA in protecting microglial cells from apoptotic death induced by the ANT2-mediated signaling pathway.	2-chloro-N(6)cyclopentyladenosine	58-63	solute carrier family 25 member 6	Homo sapiens	67-71
33592249-7	2021	This is the first report to suggest the direct binding of 2ccPA to ANT2 in microglial cells and provides evidence for a new benefit of 2ccPA in protecting microglial cells from apoptotic death induced by the ANT2-mediated signaling pathway.	2-chloro-N(6)cyclopentyladenosine	58-63	solute carrier family 25 member 6	Homo sapiens	208-212
33592249-7	2021	This is the first report to suggest the direct binding of 2ccPA to ANT2 in microglial cells and provides evidence for a new benefit of 2ccPA in protecting microglial cells from apoptotic death induced by the ANT2-mediated signaling pathway.	2-chloro-N(6)cyclopentyladenosine	135-140	solute carrier family 25 member 6	Homo sapiens	208-212
33511551-4	2021	NECA (adenosine-analog) and CCPA (adenosine A1 receptor-agonist)-induced dose-dependent vascular response was tested with t-AUCB (sEH-inhibitor) and angiotensin-II (Ang-II) in A2AAR-/- vs. C57Bl/6 mice.	2-chloro-N(6)cyclopentyladenosine	28-32	epoxide hydrolase 2, cytoplasmic	Mus musculus	130-133
33511551-4	2021	NECA (adenosine-analog) and CCPA (adenosine A1 receptor-agonist)-induced dose-dependent vascular response was tested with t-AUCB (sEH-inhibitor) and angiotensin-II (Ang-II) in A2AAR-/- vs. C57Bl/6 mice.	2-chloro-N(6)cyclopentyladenosine	28-32	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	149-163
33511551-4	2021	NECA (adenosine-analog) and CCPA (adenosine A1 receptor-agonist)-induced dose-dependent vascular response was tested with t-AUCB (sEH-inhibitor) and angiotensin-II (Ang-II) in A2AAR-/- vs. C57Bl/6 mice.	2-chloro-N(6)cyclopentyladenosine	28-32	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	165-171
33511551-4	2021	NECA (adenosine-analog) and CCPA (adenosine A1 receptor-agonist)-induced dose-dependent vascular response was tested with t-AUCB (sEH-inhibitor) and angiotensin-II (Ang-II) in A2AAR-/- vs. C57Bl/6 mice.	2-chloro-N(6)cyclopentyladenosine	28-32	adenosine A2a receptor	Mus musculus	176-181
33511551-5	2021	In A2AAR-/-, NECA and CCPA-induced increase in dose-dependent vasoconstriction compared to C57Bl/6 mice.	2-chloro-N(6)cyclopentyladenosine	22-26	adenosine A2a receptor	Mus musculus	3-8
33511551-6	2021	However, NECA and CCPA-induced dose-dependent vascular contraction in A2AAR-/- was reduced by t-AUCB with NECA.	2-chloro-N(6)cyclopentyladenosine	18-22	adenosine A2a receptor	Mus musculus	70-75
33511551-7	2021	Similarly, dose-dependent vascular contraction in A2AAR-/- was reduced by t-AUCB with CCPA.	2-chloro-N(6)cyclopentyladenosine	86-90	adenosine A2a receptor	Mus musculus	50-55
33511551-8	2021	In addition, Ang-II enhanced NECA and CCPA-induced dose-dependent vascular contraction in A2AAR-/- with NECA.	2-chloro-N(6)cyclopentyladenosine	38-42	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	13-19
33511551-8	2021	In addition, Ang-II enhanced NECA and CCPA-induced dose-dependent vascular contraction in A2AAR-/- with NECA.	2-chloro-N(6)cyclopentyladenosine	38-42	adenosine A2a receptor	Mus musculus	90-95
33511551-9	2021	Similarly, the dose-dependent vascular contraction in A2AAR-/- was also enhanced by Ang-II with CCPA.	2-chloro-N(6)cyclopentyladenosine	96-100	adenosine A2a receptor	Mus musculus	54-59
33511551-9	2021	Similarly, the dose-dependent vascular contraction in A2AAR-/- was also enhanced by Ang-II with CCPA.	2-chloro-N(6)cyclopentyladenosine	96-100	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	84-90
33511551-10	2021	Further, t-AUCB reduced Ang-II-enhanced NECA and CCPA-induced dose-dependent vascular contraction in A2AAR-/- mice.	2-chloro-N(6)cyclopentyladenosine	49-53	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	24-30
33511551-10	2021	Further, t-AUCB reduced Ang-II-enhanced NECA and CCPA-induced dose-dependent vascular contraction in A2AAR-/- mice.	2-chloro-N(6)cyclopentyladenosine	49-53	adenosine A2a receptor	Mus musculus	101-106
32206061-4	2020	The activation of A1AR and inactivation of A2aAR by 2-chloro-N6-cyclopentyladenosine (CCPA) and SCH58251, respectively, partly reversed OGD-mediated glutamate uptake dysfunction, elevated EAAT2, and PPARgamma protein levels, and suppressed the expression of Ying Yang 1 (YY1).	2-chloro-N(6)cyclopentyladenosine	52-84	solute carrier family 1 member 2	Homo sapiens	188-193
33325565-2	2021	Most functional assessments of CcpA, including interaction with its key co-factor HPr, have been performed in non-pathogenic bacteria.	2-chloro-N(6)cyclopentyladenosine	31-35	haptoglobin-related protein	Homo sapiens	82-85
33325565-3	2021	In this study we aimed to identify the in vivo DNA binding profile of CcpA and assess the extent to which HPr is required for CcpA-mediated regulation and DNA binding in the major human pathogen group A Streptococcus (GAS).	2-chloro-N(6)cyclopentyladenosine	126-130	haptoglobin-related protein	Homo sapiens	106-109
33325565-6	2021	Mutating CcpA Val301 to Ala (strain 2221-CcpA-V301A) abolished interaction between CcpA and HPr and impacted the transcript levels of 205 genes (40%) in the total CcpA regulon.	2-chloro-N(6)cyclopentyladenosine	9-13	haptoglobin-related protein	Homo sapiens	92-95
33325565-6	2021	Mutating CcpA Val301 to Ala (strain 2221-CcpA-V301A) abolished interaction between CcpA and HPr and impacted the transcript levels of 205 genes (40%) in the total CcpA regulon.	2-chloro-N(6)cyclopentyladenosine	41-45	haptoglobin-related protein	Homo sapiens	92-95
33325565-6	2021	Mutating CcpA Val301 to Ala (strain 2221-CcpA-V301A) abolished interaction between CcpA and HPr and impacted the transcript levels of 205 genes (40%) in the total CcpA regulon.	2-chloro-N(6)cyclopentyladenosine	41-45	haptoglobin-related protein	Homo sapiens	92-95
33325565-8	2021	These data delineate the direct CcpA regulon and clarify the HPr-dependent and independent activities of CcpA in a key pathogenic bacterium.	2-chloro-N(6)cyclopentyladenosine	105-109	haptoglobin-related protein	Homo sapiens	61-64
32612520-4	2020	We found that the selective A1R agonist CCPA caused a lasting depression of synaptic responses in both CA2 and CA1 neurons in slices obtained from juvenile rats (P14), but that the effect was observed only in CA2 in slices prepared from adult animals (~P70).	2-chloro-N(6)cyclopentyladenosine	40-44	carbonic anhydrase 2	Rattus norvegicus	103-106
32612520-4	2020	We found that the selective A1R agonist CCPA caused a lasting depression of synaptic responses in both CA2 and CA1 neurons in slices obtained from juvenile rats (P14), but that the effect was observed only in CA2 in slices prepared from adult animals (~P70).	2-chloro-N(6)cyclopentyladenosine	40-44	carbonic anhydrase 1	Rattus norvegicus	111-114
32612520-4	2020	We found that the selective A1R agonist CCPA caused a lasting depression of synaptic responses in both CA2 and CA1 neurons in slices obtained from juvenile rats (P14), but that the effect was observed only in CA2 in slices prepared from adult animals (~P70).	2-chloro-N(6)cyclopentyladenosine	40-44	carbonic anhydrase 2	Rattus norvegicus	209-212
33537802-9	2021	The results also demonstrated that PSH inhibited the expression of ARA1, and the agonist of ARA1, 2-chloro-N6-cyclopentyladenosine, reversed the effects of PSH.	2-chloro-N(6)cyclopentyladenosine	98-130	spliceosome associated factor 1, recruiter of U4/U6.U5 tri-snRNP	Homo sapiens	92-96
32612520-5	2020	Interestingly, blocking phosphodiesterase activity with rolipram inhibited the CCPA-induced depression in CA1, but not in CA2, indicative of robust phosphodiesterase activity in CA1 neurons.	2-chloro-N(6)cyclopentyladenosine	79-83	carbonic anhydrase 1	Rattus norvegicus	106-109
32612520-5	2020	Interestingly, blocking phosphodiesterase activity with rolipram inhibited the CCPA-induced depression in CA1, but not in CA2, indicative of robust phosphodiesterase activity in CA1 neurons.	2-chloro-N(6)cyclopentyladenosine	79-83	carbonic anhydrase 1	Rattus norvegicus	178-181
32206061-4	2020	The activation of A1AR and inactivation of A2aAR by 2-chloro-N6-cyclopentyladenosine (CCPA) and SCH58251, respectively, partly reversed OGD-mediated glutamate uptake dysfunction, elevated EAAT2, and PPARgamma protein levels, and suppressed the expression of Ying Yang 1 (YY1).	2-chloro-N(6)cyclopentyladenosine	86-90	solute carrier family 1 member 2	Homo sapiens	188-193
32206061-4	2020	The activation of A1AR and inactivation of A2aAR by 2-chloro-N6-cyclopentyladenosine (CCPA) and SCH58251, respectively, partly reversed OGD-mediated glutamate uptake dysfunction, elevated EAAT2, and PPARgamma protein levels, and suppressed the expression of Ying Yang 1 (YY1).	2-chloro-N(6)cyclopentyladenosine	86-90	peroxisome proliferator activated receptor gamma	Homo sapiens	199-208
32206061-4	2020	The activation of A1AR and inactivation of A2aAR by 2-chloro-N6-cyclopentyladenosine (CCPA) and SCH58251, respectively, partly reversed OGD-mediated glutamate uptake dysfunction, elevated EAAT2, and PPARgamma protein levels, and suppressed the expression of Ying Yang 1 (YY1).	2-chloro-N(6)cyclopentyladenosine	86-90	YY1 transcription factor	Homo sapiens	271-274
32206061-4	2020	The activation of A1AR and inactivation of A2aAR by 2-chloro-N6-cyclopentyladenosine (CCPA) and SCH58251, respectively, partly reversed OGD-mediated glutamate uptake dysfunction, elevated EAAT2, and PPARgamma protein levels, and suppressed the expression of Ying Yang 1 (YY1).	2-chloro-N(6)cyclopentyladenosine	52-84	peroxisome proliferator activated receptor gamma	Homo sapiens	199-208
32206061-4	2020	The activation of A1AR and inactivation of A2aAR by 2-chloro-N6-cyclopentyladenosine (CCPA) and SCH58251, respectively, partly reversed OGD-mediated glutamate uptake dysfunction, elevated EAAT2, and PPARgamma protein levels, and suppressed the expression of Ying Yang 1 (YY1).	2-chloro-N(6)cyclopentyladenosine	52-84	YY1 transcription factor	Homo sapiens	271-274
30347181-9	2019	In MAs, higher 2-Chloro-N6-cyclopentyladenosine (CCPA, selective A1AR agonist) induced contractions in hypertensive mice were observed.	2-chloro-N(6)cyclopentyladenosine	15-47	adenosine A1 receptor	Mus musculus	65-69
30347181-9	2019	In MAs, higher 2-Chloro-N6-cyclopentyladenosine (CCPA, selective A1AR agonist) induced contractions in hypertensive mice were observed.	2-chloro-N(6)cyclopentyladenosine	49-53	adenosine A1 receptor	Mus musculus	65-69
28855189-5	2017	However, CCPA-induced [Ca2+]i elevation is dependent on phospholipase C and transient receptor potential cation channel, subfamily C, member 3 (TRPC3).	2-chloro-N(6)cyclopentyladenosine	9-13	transient receptor potential cation channel subfamily C member 3	Sus scrofa	144-149
29380238-5	2018	In our research, we find that the stimulation of the ADORA1 by CCPA accelerated the injury of PC12 cells as well as upregulated the expression of PKC, inwardly rectifying potassium channel 6.2(Kir6.2) and sulfonylurea receptor 1(SUR1) while inhibition of the ADORA1 by DPCPX alleviated the injury of PC12 cells as well as downregulated the expression of PKC, Kir6.2, and SUR1.	2-chloro-N(6)cyclopentyladenosine	63-67	adenosine A1 receptor	Rattus norvegicus	53-59
29380238-5	2018	In our research, we find that the stimulation of the ADORA1 by CCPA accelerated the injury of PC12 cells as well as upregulated the expression of PKC, inwardly rectifying potassium channel 6.2(Kir6.2) and sulfonylurea receptor 1(SUR1) while inhibition of the ADORA1 by DPCPX alleviated the injury of PC12 cells as well as downregulated the expression of PKC, Kir6.2, and SUR1.	2-chloro-N(6)cyclopentyladenosine	63-67	protein kinase C, gamma	Rattus norvegicus	146-149
29380238-5	2018	In our research, we find that the stimulation of the ADORA1 by CCPA accelerated the injury of PC12 cells as well as upregulated the expression of PKC, inwardly rectifying potassium channel 6.2(Kir6.2) and sulfonylurea receptor 1(SUR1) while inhibition of the ADORA1 by DPCPX alleviated the injury of PC12 cells as well as downregulated the expression of PKC, Kir6.2, and SUR1.	2-chloro-N(6)cyclopentyladenosine	63-67	potassium inwardly-rectifying channel, subfamily J, member 11	Rattus norvegicus	193-199
29380238-5	2018	In our research, we find that the stimulation of the ADORA1 by CCPA accelerated the injury of PC12 cells as well as upregulated the expression of PKC, inwardly rectifying potassium channel 6.2(Kir6.2) and sulfonylurea receptor 1(SUR1) while inhibition of the ADORA1 by DPCPX alleviated the injury of PC12 cells as well as downregulated the expression of PKC, Kir6.2, and SUR1.	2-chloro-N(6)cyclopentyladenosine	63-67	ATP binding cassette subfamily C member 8	Rattus norvegicus	205-228
29380238-5	2018	In our research, we find that the stimulation of the ADORA1 by CCPA accelerated the injury of PC12 cells as well as upregulated the expression of PKC, inwardly rectifying potassium channel 6.2(Kir6.2) and sulfonylurea receptor 1(SUR1) while inhibition of the ADORA1 by DPCPX alleviated the injury of PC12 cells as well as downregulated the expression of PKC, Kir6.2, and SUR1.	2-chloro-N(6)cyclopentyladenosine	63-67	ATP binding cassette subfamily C member 8	Rattus norvegicus	229-233
29380238-5	2018	In our research, we find that the stimulation of the ADORA1 by CCPA accelerated the injury of PC12 cells as well as upregulated the expression of PKC, inwardly rectifying potassium channel 6.2(Kir6.2) and sulfonylurea receptor 1(SUR1) while inhibition of the ADORA1 by DPCPX alleviated the injury of PC12 cells as well as downregulated the expression of PKC, Kir6.2, and SUR1.	2-chloro-N(6)cyclopentyladenosine	63-67	adenosine A1 receptor	Rattus norvegicus	259-265
29380238-5	2018	In our research, we find that the stimulation of the ADORA1 by CCPA accelerated the injury of PC12 cells as well as upregulated the expression of PKC, inwardly rectifying potassium channel 6.2(Kir6.2) and sulfonylurea receptor 1(SUR1) while inhibition of the ADORA1 by DPCPX alleviated the injury of PC12 cells as well as downregulated the expression of PKC, Kir6.2, and SUR1.	2-chloro-N(6)cyclopentyladenosine	63-67	protein kinase C, gamma	Rattus norvegicus	354-357
29380238-5	2018	In our research, we find that the stimulation of the ADORA1 by CCPA accelerated the injury of PC12 cells as well as upregulated the expression of PKC, inwardly rectifying potassium channel 6.2(Kir6.2) and sulfonylurea receptor 1(SUR1) while inhibition of the ADORA1 by DPCPX alleviated the injury of PC12 cells as well as downregulated the expression of PKC, Kir6.2, and SUR1.	2-chloro-N(6)cyclopentyladenosine	63-67	potassium inwardly-rectifying channel, subfamily J, member 11	Rattus norvegicus	359-365
29380238-5	2018	In our research, we find that the stimulation of the ADORA1 by CCPA accelerated the injury of PC12 cells as well as upregulated the expression of PKC, inwardly rectifying potassium channel 6.2(Kir6.2) and sulfonylurea receptor 1(SUR1) while inhibition of the ADORA1 by DPCPX alleviated the injury of PC12 cells as well as downregulated the expression of PKC, Kir6.2, and SUR1.	2-chloro-N(6)cyclopentyladenosine	63-67	ATP binding cassette subfamily C member 8	Rattus norvegicus	371-375
27012212-5	2016	This study aimed to determine whether metabolically stabilized cPA, in the form of a carba-derivative of cPA (2ccPA), could reduce plasma cholesterol levels and affect the expression of genes related to atherosclerosis in apolipoprotein E-knockout (apoE(-/-)) mice.	2-chloro-N(6)cyclopentyladenosine	110-115	apolipoprotein E	Mus musculus	222-238
28137984-5	2017	The ability of TNAP inhibition to blunt renovascular responses to norepinephrine was mostly prevented or reversed by restoring A1-adenosinergic tone with the A1-receptor agonist 2-chloro-N6-cyclopentyladenosine (100 nmol/L).	2-chloro-N(6)cyclopentyladenosine	178-210	alkaline phosphatase, biomineralization associated	Rattus norvegicus	15-19
27629787-6	2016	Our data revealed that NECA (a non-selective adenosine receptors agonist)-induced relaxation was significantly reduced in Tie2-sEH Tr mice, and CCPA (A1AR agonist)-induced contraction was increased in Tie2-sEH Tr mice.	2-chloro-N(6)cyclopentyladenosine	144-148	adenosine A1 receptor	Mus musculus	150-154
27629787-6	2016	Our data revealed that NECA (a non-selective adenosine receptors agonist)-induced relaxation was significantly reduced in Tie2-sEH Tr mice, and CCPA (A1AR agonist)-induced contraction was increased in Tie2-sEH Tr mice.	2-chloro-N(6)cyclopentyladenosine	144-148	epoxide hydrolase 2, cytoplasmic	Mus musculus	201-212
27848069-7	2017	IPC and CCPA also prevented the I/R-induced susceptibility to calcium-induced mitochondrial permeability transition, the rate of reactive oxygen species (ROS) generation, and the decreased mitochondrial content of phospho-Ser9 GSK-3beta.	2-chloro-N(6)cyclopentyladenosine	8-12	glycogen synthase kinase 3 beta	Rattus norvegicus	227-236
27662851-6	2016	Compared with the control groups on week 2, 4 and 6, in CCPA-treated groups, the ratio of P-mTOR/mTOR, expression of MBP and IL-10 increased markedly, while the expression of TNF-alpha reduced at week 6.	2-chloro-N(6)cyclopentyladenosine	56-60	mechanistic target of rapamycin kinase	Homo sapiens	90-96
27662851-6	2016	Compared with the control groups on week 2, 4 and 6, in CCPA-treated groups, the ratio of P-mTOR/mTOR, expression of MBP and IL-10 increased markedly, while the expression of TNF-alpha reduced at week 6.	2-chloro-N(6)cyclopentyladenosine	56-60	mechanistic target of rapamycin kinase	Homo sapiens	92-96
27662851-6	2016	Compared with the control groups on week 2, 4 and 6, in CCPA-treated groups, the ratio of P-mTOR/mTOR, expression of MBP and IL-10 increased markedly, while the expression of TNF-alpha reduced at week 6.	2-chloro-N(6)cyclopentyladenosine	56-60	myelin basic protein	Homo sapiens	117-120
27662851-6	2016	Compared with the control groups on week 2, 4 and 6, in CCPA-treated groups, the ratio of P-mTOR/mTOR, expression of MBP and IL-10 increased markedly, while the expression of TNF-alpha reduced at week 6.	2-chloro-N(6)cyclopentyladenosine	56-60	interleukin 10	Homo sapiens	125-130
27662851-6	2016	Compared with the control groups on week 2, 4 and 6, in CCPA-treated groups, the ratio of P-mTOR/mTOR, expression of MBP and IL-10 increased markedly, while the expression of TNF-alpha reduced at week 6.	2-chloro-N(6)cyclopentyladenosine	56-60	tumor necrosis factor	Homo sapiens	175-184
27012212-5	2016	This study aimed to determine whether metabolically stabilized cPA, in the form of a carba-derivative of cPA (2ccPA), could reduce plasma cholesterol levels and affect the expression of genes related to atherosclerosis in apolipoprotein E-knockout (apoE(-/-)) mice.	2-chloro-N(6)cyclopentyladenosine	110-115	apolipoprotein E	Mus musculus	249-253
27012212-7	2016	2ccPA also reduced expression of lipid metabolism-related genes, cytokines, and chemokines in ApoE-deficient mice on a high-fat diet.	2-chloro-N(6)cyclopentyladenosine	0-5	apolipoprotein E	Mus musculus	94-98
27012212-8	2016	Taken together, these results suggest that 2ccPA governs anti-atherogenic activities in the carotid arteries of apoE-deficient mice.	2-chloro-N(6)cyclopentyladenosine	43-48	apolipoprotein E	Mus musculus	112-116
25557798-9	2015	Interestingly, NMDA preconditioning also induced antinociception in the hot plate test and both effects were reversed by post-activation of A1R with the agonist CCPA (0.2mg/kg, i.p.).	2-chloro-N(6)cyclopentyladenosine	161-165	adenosine A1 receptor	Mus musculus	140-143
25725289-6	2015	Direct activation of PKC with PMA or indirect activation with the adenosine A1 receptor agonist 2-chloro-N(6)-cyclopentyladenosine (CCPA) led to significant increases in [(3)H]NBMPR binding and [(3)H]2-chloroadenosine uptake in WT-hENT1 transfected cells.	2-chloro-N(6)cyclopentyladenosine	96-130	protein kinase C delta	Homo sapiens	21-24
25725289-6	2015	Direct activation of PKC with PMA or indirect activation with the adenosine A1 receptor agonist 2-chloro-N(6)-cyclopentyladenosine (CCPA) led to significant increases in [(3)H]NBMPR binding and [(3)H]2-chloroadenosine uptake in WT-hENT1 transfected cells.	2-chloro-N(6)cyclopentyladenosine	96-130	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	231-236
25725289-6	2015	Direct activation of PKC with PMA or indirect activation with the adenosine A1 receptor agonist 2-chloro-N(6)-cyclopentyladenosine (CCPA) led to significant increases in [(3)H]NBMPR binding and [(3)H]2-chloroadenosine uptake in WT-hENT1 transfected cells.	2-chloro-N(6)cyclopentyladenosine	132-136	protein kinase C delta	Homo sapiens	21-24
25725289-6	2015	Direct activation of PKC with PMA or indirect activation with the adenosine A1 receptor agonist 2-chloro-N(6)-cyclopentyladenosine (CCPA) led to significant increases in [(3)H]NBMPR binding and [(3)H]2-chloroadenosine uptake in WT-hENT1 transfected cells.	2-chloro-N(6)cyclopentyladenosine	132-136	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	231-236
25725289-7	2015	The PKC inhibitor Go6983 blocked these effects of both PMA and CCPA, and the CCPA-mediated increase was also blocked by the A1 adenosine receptor antagonist DPCPX.	2-chloro-N(6)cyclopentyladenosine	63-67	protein kinase C delta	Homo sapiens	4-7
24274595-5	2014	Compared with macrophages from healthy subjects, CCPA macrophages showed unrestrained rises in IL1A, IL1B, IL6, IRAK2 and TRAF6 throughout the experiment, and a lack of expression of TGFB1 at 9 h. Single nucleotide polymorphisms (SNPs) associated with CCPA were found in IL1B (n = 2), IL1RN and IL15 (n = 3).	2-chloro-N(6)cyclopentyladenosine	49-53	interleukin 1 beta	Homo sapiens	271-275
25193981-4	2015	METHODS: PPBP expression by monocyte-derived macrophages from patients with ABPA or CCPA and asthmatic and healthy controls (10 individuals per group) was analyzed using reverse-transcription polymerase chain reaction.	2-chloro-N(6)cyclopentyladenosine	84-88	pro-platelet basic protein	Homo sapiens	9-13
25193981-10	2015	IL-10 protein levels were significantly lower in the ABPA and CCPA groups, compared with the healthy group, suggesting that differences in PPBP levels may result from regulatory mechanisms.	2-chloro-N(6)cyclopentyladenosine	62-66	interleukin 10	Homo sapiens	0-5
25193981-10	2015	IL-10 protein levels were significantly lower in the ABPA and CCPA groups, compared with the healthy group, suggesting that differences in PPBP levels may result from regulatory mechanisms.	2-chloro-N(6)cyclopentyladenosine	62-66	pro-platelet basic protein	Homo sapiens	139-143
24274595-5	2014	Compared with macrophages from healthy subjects, CCPA macrophages showed unrestrained rises in IL1A, IL1B, IL6, IRAK2 and TRAF6 throughout the experiment, and a lack of expression of TGFB1 at 9 h. Single nucleotide polymorphisms (SNPs) associated with CCPA were found in IL1B (n = 2), IL1RN and IL15 (n = 3).	2-chloro-N(6)cyclopentyladenosine	49-53	interleukin 1 receptor associated kinase 2	Homo sapiens	112-117
24712925-5	2014	Single-nucleotide polymorphisms (SNPs) associated with CCPA were found in TLR1, CLEC7A (dectin-1), PLAT (n=2), VEGFA, and DENND1B.	2-chloro-N(6)cyclopentyladenosine	55-59	toll like receptor 1	Homo sapiens	74-78
24712925-5	2014	Single-nucleotide polymorphisms (SNPs) associated with CCPA were found in TLR1, CLEC7A (dectin-1), PLAT (n=2), VEGFA, and DENND1B.	2-chloro-N(6)cyclopentyladenosine	55-59	C-type lectin domain containing 7A	Homo sapiens	80-86
24712925-5	2014	Single-nucleotide polymorphisms (SNPs) associated with CCPA were found in TLR1, CLEC7A (dectin-1), PLAT (n=2), VEGFA, and DENND1B.	2-chloro-N(6)cyclopentyladenosine	55-59	C-type lectin domain containing 7A	Homo sapiens	88-96
24712925-5	2014	Single-nucleotide polymorphisms (SNPs) associated with CCPA were found in TLR1, CLEC7A (dectin-1), PLAT (n=2), VEGFA, and DENND1B.	2-chloro-N(6)cyclopentyladenosine	55-59	plasminogen activator, tissue type	Homo sapiens	99-103
24712925-5	2014	Single-nucleotide polymorphisms (SNPs) associated with CCPA were found in TLR1, CLEC7A (dectin-1), PLAT (n=2), VEGFA, and DENND1B.	2-chloro-N(6)cyclopentyladenosine	55-59	vascular endothelial growth factor A	Homo sapiens	111-116
24712925-5	2014	Single-nucleotide polymorphisms (SNPs) associated with CCPA were found in TLR1, CLEC7A (dectin-1), PLAT (n=2), VEGFA, and DENND1B.	2-chloro-N(6)cyclopentyladenosine	55-59	DENN domain containing 1B	Homo sapiens	122-129
24274595-5	2014	Compared with macrophages from healthy subjects, CCPA macrophages showed unrestrained rises in IL1A, IL1B, IL6, IRAK2 and TRAF6 throughout the experiment, and a lack of expression of TGFB1 at 9 h. Single nucleotide polymorphisms (SNPs) associated with CCPA were found in IL1B (n = 2), IL1RN and IL15 (n = 3).	2-chloro-N(6)cyclopentyladenosine	49-53	TNF receptor associated factor 6	Homo sapiens	122-127
24274595-5	2014	Compared with macrophages from healthy subjects, CCPA macrophages showed unrestrained rises in IL1A, IL1B, IL6, IRAK2 and TRAF6 throughout the experiment, and a lack of expression of TGFB1 at 9 h. Single nucleotide polymorphisms (SNPs) associated with CCPA were found in IL1B (n = 2), IL1RN and IL15 (n = 3).	2-chloro-N(6)cyclopentyladenosine	49-53	interleukin 1 receptor antagonist	Homo sapiens	285-290
24274595-5	2014	Compared with macrophages from healthy subjects, CCPA macrophages showed unrestrained rises in IL1A, IL1B, IL6, IRAK2 and TRAF6 throughout the experiment, and a lack of expression of TGFB1 at 9 h. Single nucleotide polymorphisms (SNPs) associated with CCPA were found in IL1B (n = 2), IL1RN and IL15 (n = 3).	2-chloro-N(6)cyclopentyladenosine	49-53	interleukin 15	Homo sapiens	295-299
24274595-7	2014	The association of SNPs in IL1B, IL1RN and IL15 with CCPA supports a role for the IL1 pathway, as well as implicating the IL15 gene, in susceptibility to CCPA.	2-chloro-N(6)cyclopentyladenosine	53-57	interleukin 1 beta	Homo sapiens	27-31
24274595-7	2014	The association of SNPs in IL1B, IL1RN and IL15 with CCPA supports a role for the IL1 pathway, as well as implicating the IL15 gene, in susceptibility to CCPA.	2-chloro-N(6)cyclopentyladenosine	53-57	interleukin 1 receptor antagonist	Homo sapiens	33-38
24274595-5	2014	Compared with macrophages from healthy subjects, CCPA macrophages showed unrestrained rises in IL1A, IL1B, IL6, IRAK2 and TRAF6 throughout the experiment, and a lack of expression of TGFB1 at 9 h. Single nucleotide polymorphisms (SNPs) associated with CCPA were found in IL1B (n = 2), IL1RN and IL15 (n = 3).	2-chloro-N(6)cyclopentyladenosine	49-53	interleukin 1 alpha	Homo sapiens	95-99
24274595-5	2014	Compared with macrophages from healthy subjects, CCPA macrophages showed unrestrained rises in IL1A, IL1B, IL6, IRAK2 and TRAF6 throughout the experiment, and a lack of expression of TGFB1 at 9 h. Single nucleotide polymorphisms (SNPs) associated with CCPA were found in IL1B (n = 2), IL1RN and IL15 (n = 3).	2-chloro-N(6)cyclopentyladenosine	49-53	interleukin 1 beta	Homo sapiens	101-105
24274595-7	2014	The association of SNPs in IL1B, IL1RN and IL15 with CCPA supports a role for the IL1 pathway, as well as implicating the IL15 gene, in susceptibility to CCPA.	2-chloro-N(6)cyclopentyladenosine	53-57	interleukin 15	Homo sapiens	43-47
24274595-7	2014	The association of SNPs in IL1B, IL1RN and IL15 with CCPA supports a role for the IL1 pathway, as well as implicating the IL15 gene, in susceptibility to CCPA.	2-chloro-N(6)cyclopentyladenosine	53-57	interleukin 1 beta	Homo sapiens	27-30
24274595-5	2014	Compared with macrophages from healthy subjects, CCPA macrophages showed unrestrained rises in IL1A, IL1B, IL6, IRAK2 and TRAF6 throughout the experiment, and a lack of expression of TGFB1 at 9 h. Single nucleotide polymorphisms (SNPs) associated with CCPA were found in IL1B (n = 2), IL1RN and IL15 (n = 3).	2-chloro-N(6)cyclopentyladenosine	49-53	interleukin 6	Homo sapiens	107-110
24274595-7	2014	The association of SNPs in IL1B, IL1RN and IL15 with CCPA supports a role for the IL1 pathway, as well as implicating the IL15 gene, in susceptibility to CCPA.	2-chloro-N(6)cyclopentyladenosine	154-158	interleukin 15	Homo sapiens	43-47
24274595-7	2014	The association of SNPs in IL1B, IL1RN and IL15 with CCPA supports a role for the IL1 pathway, as well as implicating the IL15 gene, in susceptibility to CCPA.	2-chloro-N(6)cyclopentyladenosine	154-158	interleukin 1 beta	Homo sapiens	27-30
24274595-7	2014	The association of SNPs in IL1B, IL1RN and IL15 with CCPA supports a role for the IL1 pathway, as well as implicating the IL15 gene, in susceptibility to CCPA.	2-chloro-N(6)cyclopentyladenosine	154-158	interleukin 15	Homo sapiens	122-126
25277512-0	2014	An adenosine A1 agonist 2-chloro-N6 cyclopentyladenosine inhibits the angiotensin II-induced cardiomyocyte hypertrophy through the calcineurin pathway.	2-chloro-N(6)cyclopentyladenosine	24-56	angiotensinogen	Rattus norvegicus	70-84
24560904-2	2014	In a model of peritonitis, we previously found that pharmacological preconditioning (PPC) of mice with a selective adenosine A1 receptor (A1R) agonist, 2-chloro-N(6)-cyclopentyladenosine (CCPA), induced the A2AR which reduces cytokine secretion and leukocyte recruitment.	2-chloro-N(6)cyclopentyladenosine	152-186	adenosine A2a receptor	Mus musculus	207-211
24016034-9	2014	These enhanced Fos responses were attenuated by the local application of CCPA.	2-chloro-N(6)cyclopentyladenosine	73-77	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	15-18
25277512-1	2014	OBJECTIVES: The aim of this investigation was to study the underlying mechanism of an adenosine A1 receptor agonist 2-chloro-N6 cyclopentyladenosine (CCPA) inhibiting cardiomyocyte hypertrophy induced by angiotensin II (AngII).	2-chloro-N(6)cyclopentyladenosine	116-148	angiotensinogen	Rattus norvegicus	204-218
25277512-1	2014	OBJECTIVES: The aim of this investigation was to study the underlying mechanism of an adenosine A1 receptor agonist 2-chloro-N6 cyclopentyladenosine (CCPA) inhibiting cardiomyocyte hypertrophy induced by angiotensin II (AngII).	2-chloro-N(6)cyclopentyladenosine	116-148	angiotensinogen	Rattus norvegicus	220-225
25277512-1	2014	OBJECTIVES: The aim of this investigation was to study the underlying mechanism of an adenosine A1 receptor agonist 2-chloro-N6 cyclopentyladenosine (CCPA) inhibiting cardiomyocyte hypertrophy induced by angiotensin II (AngII).	2-chloro-N(6)cyclopentyladenosine	150-154	angiotensinogen	Rattus norvegicus	204-218
25277512-1	2014	OBJECTIVES: The aim of this investigation was to study the underlying mechanism of an adenosine A1 receptor agonist 2-chloro-N6 cyclopentyladenosine (CCPA) inhibiting cardiomyocyte hypertrophy induced by angiotensin II (AngII).	2-chloro-N(6)cyclopentyladenosine	150-154	angiotensinogen	Rattus norvegicus	220-225
25277512-13	2014	CONCLUSION: The A1 receptor agonist CCPA could significantly inhibit AngII-induced cardiomyocyte hypertrophy via the calcineurin signaling pathway.	2-chloro-N(6)cyclopentyladenosine	36-40	angiotensinogen	Rattus norvegicus	69-74
23813214-4	2013	Treatment of human proximal tubule epithelial (HK-2) cells with a selective A1 adenosine receptor agonist, chloro-N(6)-cyclopentyladenosine (CCPA), induced the expression of IL-11 mRNA and protein in an extracellular signal-regulated kinase-dependent manner, and administration of CCPA in mice induced renal synthesis of IL-11.	2-chloro-N(6)cyclopentyladenosine	141-145	interleukin 11	Homo sapiens	174-179
23813214-4	2013	Treatment of human proximal tubule epithelial (HK-2) cells with a selective A1 adenosine receptor agonist, chloro-N(6)-cyclopentyladenosine (CCPA), induced the expression of IL-11 mRNA and protein in an extracellular signal-regulated kinase-dependent manner, and administration of CCPA in mice induced renal synthesis of IL-11.	2-chloro-N(6)cyclopentyladenosine	141-145	interleukin 11	Mus musculus	321-326
23813214-4	2013	Treatment of human proximal tubule epithelial (HK-2) cells with a selective A1 adenosine receptor agonist, chloro-N(6)-cyclopentyladenosine (CCPA), induced the expression of IL-11 mRNA and protein in an extracellular signal-regulated kinase-dependent manner, and administration of CCPA in mice induced renal synthesis of IL-11.	2-chloro-N(6)cyclopentyladenosine	281-285	interleukin 11	Homo sapiens	174-179
23813214-8	2013	Finally, treatment with CCPA induced sphingosine kinase-1 in HK-2 cells and wild-type mice, but not in IL-11 receptor-deficient or renal proximal tubule A1 adenosine receptor-deficient mice.	2-chloro-N(6)cyclopentyladenosine	24-28	sphingosine kinase 1	Mus musculus	37-57
23660326-8	2013	Compared with M and DMSO group, the rats" behavior was improved, the cerebral infarct volume was decreased and the Bcl-2 protein expression was up-regulated (P < 0.05) in the CCPA group.	2-chloro-N(6)cyclopentyladenosine	178-182	BCL2, apoptosis regulator	Rattus norvegicus	115-120
23977428-11	2013	Accordingly, CCPA (2-chloro-N(6)-cyclopentyladenosine; 100 nM), an A1AR-selective agonist, inhibited BK current in myocytes from WT but not A1KO mice (81+-4 vs. 100+-7% of control; p<0.05).	2-chloro-N(6)cyclopentyladenosine	13-17	adenosine A1 receptor	Mus musculus	67-71
23977428-11	2013	Accordingly, CCPA (2-chloro-N(6)-cyclopentyladenosine; 100 nM), an A1AR-selective agonist, inhibited BK current in myocytes from WT but not A1KO mice (81+-4 vs. 100+-7% of control; p<0.05).	2-chloro-N(6)cyclopentyladenosine	19-53	adenosine A1 receptor	Mus musculus	67-71
23977428-12	2013	Go6976 (100 nM), a PKCalpha inhibitor, abolished the effect of CCPA to inhibit BK current (99+-3% of control).	2-chloro-N(6)cyclopentyladenosine	63-67	protein kinase C, alpha	Mus musculus	19-27
24066228-6	2013	A1 receptor mRNA expression was increased in CD73 -/- kidneys, and 2-chloro-N6-cyclopentyladenosine (0.1 mumol/L; A1 receptor agonist) enhanced renovascular responses to norepinephrine more in CD73 -/- versus CD73 +/+ kidneys.	2-chloro-N(6)cyclopentyladenosine	67-99	5' nucleotidase, ecto	Mus musculus	193-197
24066228-6	2013	A1 receptor mRNA expression was increased in CD73 -/- kidneys, and 2-chloro-N6-cyclopentyladenosine (0.1 mumol/L; A1 receptor agonist) enhanced renovascular responses to norepinephrine more in CD73 -/- versus CD73 +/+ kidneys.	2-chloro-N(6)cyclopentyladenosine	67-99	5' nucleotidase, ecto	Mus musculus	193-197
23651584-5	2013	Better characterizing the effect of A1R stimulation on the osteogenic differentiation capability of these cells, we found that CCPA increased the: i) expression of two well known and early osteogenic markers, RUNX-2 and alkaline phosphatase (ALP), after 3 and 7DIV; ii) ALP enzyme activity at 7DIV and iii) mineralization of extracellular matrix after 21DIV.	2-chloro-N(6)cyclopentyladenosine	127-131	RUNX family transcription factor 2	Homo sapiens	209-215
23651584-5	2013	Better characterizing the effect of A1R stimulation on the osteogenic differentiation capability of these cells, we found that CCPA increased the: i) expression of two well known and early osteogenic markers, RUNX-2 and alkaline phosphatase (ALP), after 3 and 7DIV; ii) ALP enzyme activity at 7DIV and iii) mineralization of extracellular matrix after 21DIV.	2-chloro-N(6)cyclopentyladenosine	127-131	alkaline phosphatase, placental	Homo sapiens	220-240
23651584-5	2013	Better characterizing the effect of A1R stimulation on the osteogenic differentiation capability of these cells, we found that CCPA increased the: i) expression of two well known and early osteogenic markers, RUNX-2 and alkaline phosphatase (ALP), after 3 and 7DIV; ii) ALP enzyme activity at 7DIV and iii) mineralization of extracellular matrix after 21DIV.	2-chloro-N(6)cyclopentyladenosine	127-131	alkaline phosphatase, placental	Homo sapiens	242-245
23651584-5	2013	Better characterizing the effect of A1R stimulation on the osteogenic differentiation capability of these cells, we found that CCPA increased the: i) expression of two well known and early osteogenic markers, RUNX-2 and alkaline phosphatase (ALP), after 3 and 7DIV; ii) ALP enzyme activity at 7DIV and iii) mineralization of extracellular matrix after 21DIV.	2-chloro-N(6)cyclopentyladenosine	127-131	alkaline phosphatase, placental	Homo sapiens	270-273
23398646-10	2013	RESULTS: In the wild-type mice, 2-chloro-N6-cyclopentyladenosine significantly improved lung function and attenuated edema, cytokine expression, and myeloperoxidase levels compared with the vehicle-treated mice after ischemia-reperfusion.	2-chloro-N(6)cyclopentyladenosine	32-64	myeloperoxidase	Mus musculus	149-164
24371503-12	2013	Phosphorylation of cardiac tissue Akt before index ischemia was enhanced by IPC or CCPA but was significantly inhibited by HG in both groups.	2-chloro-N(6)cyclopentyladenosine	83-87	thymoma viral proto-oncogene 1	Mus musculus	34-37
22796106-4	2012	Blockade of glutamate release achieved by the mGluR2/3 agonist, LY354740 or the selective adenosine A1R agonist, CCPA as well as neurotoxic lesions of lateral entorhinal cortex reduced the ability of SKF81297 to induce ERK activation in the dentate gyrus.	2-chloro-N(6)cyclopentyladenosine	113-117	mitogen-activated protein kinase 1	Mus musculus	219-222
22695326-4	2012	A selective A(1)AR agonist (CCPA) increased the synthesis of S1P and selectively induced SK1 in mouse kidney and HK-2 cells.	2-chloro-N(6)cyclopentyladenosine	28-32	adenosine A1 receptor	Mus musculus	12-18
22695326-4	2012	A selective A(1)AR agonist (CCPA) increased the synthesis of S1P and selectively induced SK1 in mouse kidney and HK-2 cells.	2-chloro-N(6)cyclopentyladenosine	28-32	sphingosine kinase 1	Mus musculus	89-92
22695326-9	2012	Mechanistically, CCPA increased nuclear translocation of hypoxia-inducible factor-1alpha in HK-2 cells and selective hypoxia-inducible factor-1alpha inhibition blocked A(1)AR-mediated induction of SK1.	2-chloro-N(6)cyclopentyladenosine	17-21	hypoxia inducible factor 1, alpha subunit	Mus musculus	57-88
22695326-9	2012	Mechanistically, CCPA increased nuclear translocation of hypoxia-inducible factor-1alpha in HK-2 cells and selective hypoxia-inducible factor-1alpha inhibition blocked A(1)AR-mediated induction of SK1.	2-chloro-N(6)cyclopentyladenosine	17-21	adenosine A1 receptor	Mus musculus	168-174
22695326-9	2012	Mechanistically, CCPA increased nuclear translocation of hypoxia-inducible factor-1alpha in HK-2 cells and selective hypoxia-inducible factor-1alpha inhibition blocked A(1)AR-mediated induction of SK1.	2-chloro-N(6)cyclopentyladenosine	17-21	sphingosine kinase 1	Mus musculus	197-200
22560096-9	2012	RIPC or CCPA induced a significant increase in brain MnSOD (manganese SOD) activity and NO generation, and this activity was abolished by DPCPX pretreatment.	2-chloro-N(6)cyclopentyladenosine	8-12	superoxide dismutase 2	Rattus norvegicus	60-73